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Abstract (English version) 
Background  
Lecithin:cholesterol acyltransferase (LCAT) is the unique enzyme in human able to esterify 
free cholesterol in plasma. Genetic lack of LCAT affects high-density lipoprotein (HDL) 
metabolism, leading to very low plasma concentrations of these lipoproteins. LCAT was 
believed to be an important driving force behind macrophage reverse cholesterol transport 
(RCT) and therefore playing a role in atheroprotection. Despite the low plasma HDL-C, 
LCAT deficiency does not remarkably increase preclinical atherosclerosis or could even be 
protective. We hypothesized that this discrepancy can be explained by an increased 
functionality of HDL particles, that are more effective in protecting against endothelium 
dysfunction.  
Methods  
HDLs were isolated from LCAT-deficient carriers and tested in vitro for their capacity to 
promote NO production and to inhibit vascular cell adhesion molecules in endothelial cells. 
Measurement of flow-mediated vasodilation (FMD) was used as marker of endothelial 
dysfunction in vivo. Reconstituted HDL containing only apoA-I (LpA-I) or apoA-I and apoA-
II (LpA-I:A-II) were used to prove the structural responsible for increased HDL functionality. 
Ex vivo analysis of monocytes in carriers of LCAT deficiency, to assessed phenotype and 
function, was performed with fluorescence-activated cell sorter analysis, inflammatory 
stimulation and transendothelial migration assays. Comparison with other genetic 
hypoalphalipoproteinemia was conducted for the monocyte study. 
Results  
Genetic LCAT deficiency is characterized by selective depletion of LpA-I:A-II and high 
presence of immature preβ-HDL. HDLs isolated from carriers were more effective in 
promoting in vitro eNOS activation by phosphorylation and consequently NO production in 
endothelial cells, compared to controls, with a gene-dose dependent effect. Moreover, 
HDLs from carriers have an increased capability in inhibiting VCAM-1 expression. The 
effect was likely dependent on the selective depletion in LpA-I:A-II particles. In addition 
carriers’ monocyte displayed a less inflammatory phenotype compared to controls, as 
evidenced by a reduced expression of integrin CD11c, a decreased capacity to 
transmigrate and a lower production of cytokines upon stimulation. Conversely, no 
changes in monocyte immunophenotype was found in other genetic HDL deficiency.  
As in vivo confirmation, no difference in FMD was found between carriers of LCAT 
deficiency and controls. 
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Conclusions  
Despite the low plasma HDL-C concentration, LCAT deficiency is not associated with 
increased endothelial dysfunction due to the enhance efficacy of HDL particles in 
stimulating endothelial NO production and in inhibiting adhesion molecules expression, as 
well to the reduce pro-inflammatory potential of carriers’ monocytes. 
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Riassunto (Versione italiana) 
Introduzione 
La lecitin:cholesterol aciltransferasi (LCAT) è l’unico enzima nell’uomo in grado di 
esterificare il colesterolo nel plasma. Il deficit genetico di LCAT influenza il metabolismo 
delle lipoproteine ad alta densità (HDL), portando a concentrazioni plasmatiche ridotte di 
queste lipoproteine. Si ritiene che LCAT sia un’importante driving force per il trasporto 
inverso del colesterolo (RCT) nei macrofagi e che pertanto giochi un ruolo importante 
nell’ateroprotezione.  
Nonostante i bassi livelli plasmatici di HDL-C, il grado di aterosclerosi preclinica non è 
risulta aumentato nel deficit di LCAT che addirittura sembra essere protettivo. Abbiamo 
quindi ipotizzato che questa discrepanza potesse essere spiegata da un aumento della 
funzionalità delle particelle HDL che sono più efficienti nel proteggere contro la disfunzione 
endoteliale.   
Metodi  
Le HDL sono state isolate da soggetti portatori di deficit di LCAT e testate in vitro per la 
loro capacità di stimolare la produzione di NO e di inibire l’espressione di molecole di 
adesione in cellule endoteliali. La misura della vasodilatazione flusso-mediata (FMD) è 
stata utilizzata come indice in vivo di disfunzione endoteliale. HDL ricostituite, contenenti 
solo apoA-I (LpA-I) o apoA-I e apoA-II (LpA-I:A-II) sono state utilizzate per dimostrare 
come quali modifiche strutturali siano responsabili dell’aumentata funzionalità. Analisi ex 
vivo del fenotipo e della funzionalità di monociti isolati da portatori di deficit di LCAT sono 
stati condotti tramite citometria a flusso, stimolazione e saggi di transmigrazione 
endoteliale. Portatori di altri deficit genetici di HDL sono stati utilizzati come confronto. 
Risultati 
Il deficit di LCAT genetico è caratterizzato da una deplezione selettiva di LpA-I: A-II e da 
alte concentrazioni di preβ-HDL immature. Le HDL isolate dai portatori si sono dimostrate 
più efficaci nel promuovere l'attivazione di eNOS in vitro mediante fosforilazione e, di 
conseguenza, la produzione di NO nelle cellule endoteliali, rispetto ai controlli, con un 
effetto gene-dose. Inoltre, le HDL dei portatori hanno una maggiore capacità di inibire 
l'espressione di VCAM-1. L'effetto è probabilmente dipendente dalla deplezione selettiva 
in lipoproteine LpA-I:A-II. Inoltre, i monociti dei portatori presentavano un fenotipo meno 
infiammatorio rispetto ai controlli, come evidenziato dalla ridotta espressione dell’integrina 
CD11c, dalla ridotta capacità di trasmigrazione e dalla minore produzione di citochine 
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dopo stimolazione. Al contrario, nessuna variazione è stata individuata 
nell’immunofenotipo di monociti isolati in soggetti con altri deficit genetici di HDL.  
A conferma in vivo di quanto individuato precedentemente non è stata trovata alcuna 
differenza nella FMD tra portatori di deficit genetico di LCAT e controlli.  
Conclusioni 
Nonostante le ridotte concentrazioni plasmatiche di HDL-C, il deficit di LCAT non è 
associato a una maggiore disfunzione endoteliale dovuta all'aumentata efficacia delle 
particelle HDL nella stimolazione della produzione di NO endoteliale e nell'inibizione 
dell'espressione delle molecole di adesione, nonché al ridotto potenziale pro-infiammatorio 
dei monociti dei portatori.  
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Abbreviations 
ABCA1 ATP-binding cassette transporter A1 
ABCG1 ATP-binding cassette sub-family G1 
ApoA-I apolipoprotein A-I 
ApoA-II apolipoprotein A-II 
ApoB apolipoprotein B 
ATF3 activating transcription factor 3 
BMI body mass index 
CAD coronary artery disease 
CCR2 C-C chemokine receptor type 2 
CCR5 C-C chemokine receptor type 5 
CCR7 C-C chemokine receptor type 7 
CD11b cluster of differentiation 11b 
CD11c cluster of differentiation 11c 
CD29 cluster of differentiation 29 
CD36 cluster of differentiation 36 
CETP cholesteryl ester transfer protein 
CVD cardiovascular disease 
eNOS endothelial nitric oxide synthase 
FC free cholesterol 
FED fish-eye disease 
FLD familial LCAT deficiency 
FMD flow-mediated vasodilation 
HAEC human aortic endothelial cells 
HDL-C high-density lipoprotein cholesterol 
hsCRP high sensitivity C-reactive protein 
HUVEC human umbilical vein endothelial cells 
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ICAM-1 intercellular Adhesion Molecule 1 
IL-6 interleukin 6 
IL-8 interleukin 8 
IL-1β interleukin 1β 
IL-1Ra interleukin 1 receptor antagonist 
IL-10 interleukin 10 
IMT intima-media thickness 
LCAT lecithin:cholesterol acyltransferase 
LDL-C low-density liporprotein cholesterol 
LpA-I:A-II lipoprotein containing apoA-I and apoA-II 
LPS lipopolysaccharide 
LpX lipoprotein X 
MCP-1 monocyte chemoattractant protein 1 
MFI mean fluorescence intensity 
NLRP3 
nucleotide-binding domain, leucine-rich-containing family, pyrin domain-
containing-3 
NO nitric oxide 
PAF-AH platelet activating factor-acetylhydrolase 
PON1 paraoxonase 1 
POPC phosphatidylcholine 
RCT reverse cholesterol transport 
rHDL reconstituted HDL 
RPMI Roswell Park Memorial Institute medium 
rhLCAT recombinant human LCAT 
S1P sphingosine-1-phosphate 
SD standard deviation 
SEM standard error of measurement 
SR-A scavenger receptor A 
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SR-BI scavenger receptor class B type 1 
TC total cholesterol 
TEM transendothelial migration 
TG triglycerides 
TLR toll-like receptor 
TNF-α tumor necrosis factor α 
VCAM-1 vascular cell adhesion protein 1 
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INTRODUCTION 
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1. Genetic high density lipoprotein disorders 
Hypoalphalipoproteinemia is characterized by plasma high-density lipoprotein 
cholesterol (HDL-C) levels below the 5th percentile for the general population. 
Marked HDL deficiency (HDL-C < 20 mg/dL), without secondary causes 
(hypertriglyceridemia, diabetes mellitus, liver disease, etc.) is very rare (<1% 
of the population). Homozygous, compound heterozygous or heterozygous 
mutations in APOA1, ABCA1 or LCAT genes account for the 10-16% of 
cases (1).  
ApoA-I has a structural role in HDL particles that contain 2-5 molecules of 
apoA-I (2) and contributes to their anti-atherosclerotic properties, since lipid-
free apoA-I mediates cholesterol efflux through the binding with the ATP 
binding cassette transporter, sub-family A, member 1 (ABCA1) (3). 
Genetic apolipoprotein A-I (apoA-I) deficiency was first reported by Norum 
and colleagues in two sisters with very low HDL-C and premature 
cardiovascular disease (CVD) (4). Since apoA-I is essential for HDL 
biogenesis, mutations of two alleles in APOA1 gene may lead to nearly 
complete absence of apoA-I and HDL-C in plasma. Among clinical signs, 
apoA-I deficiency may be accompanied by corneal opacities or xanthomas 
(5), as well as an increased risk for premature CVD (6).  
At least 70 mutations have been identified since the discovery of ApoA-IMilano 
and only half of them are causing hypoalphalipoproteinemia (7). Furthermore, 
not all mutations have been associated with increased CVD risk (8). As the 
case of carriers of the variant R197C (ApoA-IMilano) that have extremely low 
HDL-C levels, but seem to be protected from premature CVD (9). 
After being released in the plasma apoA-I particles acquire lipids in a process 
mediated by ABCA1 transporter. Homozygous ABCA1 mutations results in 
Tangier Disease (TD) (10) an autosomal dominant disorder characterized by 
absence of mature lipid-rich HDL (11), reduced LDL-C and enlarged yellow-
orange lobulated tonsils, peripheral neuropathy (12), hepatosplenomegaly, 
corneal opacity, thrombocytopenia (13, 14). Heterozygous mutations produce 
a milder phenotype. TD is associated to increase cardiovascular risk, 
although not as great as expected, despite the severely low HDL-C (15). 
Thus, studies on the association of heterozygous mutations and 
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cardiovascular disease are not conclusive (16). More than 100 variants in 
ABCA1 have been described (7) associated with a wide range of phenotypes 
(17). 
After lipidation of lipid-free apoA-I, HDL undergo maturation by the action of 
lecithin:cholesterol acyltransferase (LCAT) that esterifies the free cholesterol 
on nascent HDL. Mutations in LCAT gene lead to very low HDL-C, with 
alteration in HDL structure and distribution (18). LCAT deficiency includes 
two rare disease: familial LCAT deficiency (FLD) and fish-eye disease (FED) 
and will be discussed later in details.  
 
2. HDL and cardiovascular disease 
Observational studies have established that HDL-C is inversely associated 
with cardiovascular disease and mortality (19, 20). This strong inverse 
association was first reported by the Framingham Heart Study, where risk of 
coronary artery (CAD) increased sharply as HDL levels fall progressively 
below 40 mg/dL (21). This observation arose the concept of “reverse 
cholesterol transport” as the mechanisms by which HDL protect against 
atherosclerosis (22). The hypothesis was supported by animal studies 
showing that HDL infusion or apoA-I overexpression inhibit or prevent 
atherosclerosis (23, 24). The association was further confirmed by  
prospective studies worldwide that included different racial and ethnic groups 
(25) (26) and patients in secondary prevention setting (27). In the PROCAM 
study men with HDL-C < 0.90 mmol/L (35 mg/dL) had a fourfold increased 
risk of coronary heart disease compared to men with higher HDL-C, 
independently of serum triglycerides levels (28). A reduction in HDL-C was 
also noticed in states that predispose to early atherosclerosis such as type 2 
diabetes (29, 30). However, human genetics studies and randomized 
controlled trials (RCT) with HDL-C raising drugs however have failed in 
demonstrating benefit in reducing CV risk (31). Despite HDL-C 
concentrations, none of the three Mendelian disorders causing primary 
hypoalphalipoproteinemia (mutations in ABCA1, APOA1, LCAT gene) is 
unequivocally associated with premature coronary heart disease (32-35). 
Low-frequency and common genetic variants associated with raised HDL-C 
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concentrations, e.g. LIPG, have not proven any association with protection 
from coronary heart disease (36). One of the major issue concern the relation 
of HDL-C to other lipoproteins, thus the direct effect of HDL on 
atherosclerosis cannot be unravelled. Some reports on CETP gene variants 
showed higher HDL-C concentrations and reduced cardiovascular risk, 
however other atherogenic lipoproteins were lower in carriers compared to 
controls, thus affecting the interpretation of results (37). Moreover, some 
genetic variants associated with increased HDL-C have been paradoxically 
linked with higher risk (38) (39).  
In addition, data from clinical trials did not show a beneficial effect on 
cardiovascular risk despite the increase in HDL-C concentrations. Outcome 
trials with niacin (AIM-HIGH and HPS2-THRIVE), failed to meet the primary 
endpoint (40, 41). More dramatically, trials with CETP inhibitors were stopped 
for futility (42) or even for the increased coronary events and mortality (43), 
despite the efficacy in arising HDL-C levels was clear. Very recently outcome 
data on anacetrapib showed that this CETP inhibitor was able to reduce by 
9% the occurrence of major cardiovascular events, however the results have 
been considered non satisfactory and LDL-C reduction was advocate as the 
main responsible of this positive effect (44). 
Very recently Madsen and colleagues have demonstrated on a large number 
of subjects (more than 100 000) a U-shaped association between HDL-C and 
cardiovascular mortality in both men and women (Figure 1). The same was 
found when single cardiovascular endpoints were considered (ischemic heart 
disease, myocardial infarction and ischemic stroke) (45).  
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Figure 1. HDL cholesterol on a continuous scale and risk of cardiovascular, 
cancer, and other mortality in the general population. Solid line represents 
hazard ratio and dashed lines represent 95% confidence interval. Adapted 
from (45). 
 
In summary, although in epidemiological studies the inverse relation between 
HDL-C and cardiovascular risk is clear and strong, RCT and human genetics 
are not supporting the observation.  
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In the last years it has become more evident that the HDL hypothesis needed 
a recasting to a different concept that is the HDL function hypothesis (46): it 
is not HDL-C itself that has a causal relation with atheroprotection, but rather 
HDL function. 
 
3. HDL and endothelial protection  
Human HDLs are an heterogeneous class of lipoproteins. Each subclass 
express a different activity and the variety of effect displayed by HDL reflects 
the numerous amount of protein surrounding the particles, that can act 
synergistically (47, 48). Most of them contain apoA-I as the mayor 
component, but several other proteins are associated with HDL and confer 
physiological functions. Among these, apoA-II, apoCs, apoE, LCAT, PON, 
PAF-AH are the most important. Moreover, lipids and proteins composition 
contributes in defining different properties.  
HDL has been shown to have various properties that can contribute to confer 
cardiovascular protection [44], dependent on their protective effect on 
vascular endothelium, which dysfunction represents a key early step of 
atherosclerosis development and is implicated in plaque progression and 
destabilization (Figure 2).  
Endothelial dysfunction has been reported in primary 
hypoalphalipoproteinemia (49, 50). The effect of HDL on vascular 
endothelium translated in vivo into HDL-mediated endothelial protection and 
may be relevant in the development and prevention of vascular disease.  
To this regards, maintenance of vascular endothelium homeostasis is crucial 
and HDL can contribute positively affecting several endothelial functions in 
the regulation of vascular tone, inflammation and hemostasis.  
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Figure 2. Multiple biological actions of HDL on vascular endothelium (51). 
 
Cholesterol efflux 
The best known HDL property resides in its ability to promote cholesterol 
efflux from peripheral cells, in particular from macrophages, and the related 
physiological process of reverse cholesterol transport (52). Lipid-poor apoA-I 
is an efficient acceptor of cholesterol and phospholipids via the ABCA1 
transporter, that promote a fast, saturable and unidirectional efflux. This 
efflux permits the composition of small discoidal preβ-HDL, which can 
remove further cholesterol by the same pathway (53). Mature HDL can efflux 
cholesterol by ATP-binding cassette transporter G1 (ABCG1) and scavenger 
receptor class B type 1 (SR-BI) (54), mediating cholesterol efflux to large 
spherical HDL2 and HDL3 after their growth permit by the action ABCA1 and 
LCAT on small preβ-HDL. ABCG1 deletion in macrophages does not 
aggravate atherosclerosis demonstrating that ABCG1-mediated pathway of 
cholesterol efflux from macrophages appears to be quantitatively less 
important compared with that of ABCA1. But ABCA1 and ABCG1 may act 
synergistically in enhancing cellular cholesterol efflux (55, 56). 
SR-BI mediates a slow, unsaturable and bi-directional efflux, that occur by 
passive diffusion. It acts on large, mature phospholipid-rich-HDL. The 
phospholipid content represent the principal characteristic that allow SR-BI 
binding. It acts primarily in hepatocytes but also in macrophages, adipocytes 
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and other cell types (57). Cholesterol transferred to HDL is then esterified 
under the action of LCAT and move to the lipid core of HDL helping to 
maintain a free-cholesterol gradient from cells to HDL. Recent data suggest 
that RCT can occur in the absence of functional LCAT (58, 59). The major of 
cholesteryl esters are transferred to the apoB containing particles thanks to 
CETP and metabolized into the liver. Alternatively HDL are taken-up by the 
liver through SR-BI, or SR-BI can also take-up unesterified cholesterol into 
the liver. 
Cholesterol efflux power differs between HDL subpopulations. It depends on 
the transporter or receptor that HDL can activate: small discoidal preβ-HDL 
activate ABCA1, large spherical HDL activate ABCG1 and SR-BI. It depends 
on size and density: smaller particles are more potently inducers of 
cholesterol efflux. Finally it depends on apolipoprotein composition: LpA-I are 
more active than LpA-I:A-II. Modification of apoA-I by myeloperoxidase 
affects its ability to promote cholesterol efflux and apoA-I modified by 
myeloperoxidase is abundant in human atheroma (60). The correlation 
between HDL-C and efflux capacity is weak, thus suggesting that HDL-C 
does not predict the ability of HDL to promote reverse cholesterol transport.  
Then, it has been suggested that cholesterol efflux capacity is more precise 
and predictive marker of atherosclerosis progression, compared to HDL-C 
(52).  
 
Antioxidant effects 
Oxidative stress in the arterial wall modified LDL to oxidized-LDL that are 
associated with the development of atherosclerotic plaque. The atherogenic 
property of oxidized-LDL is to accumulate in arterial wall cells, principally in 
macrophages that after phagocytising oxidized-LDL turn to foam cell, main 
representatives of the plaque.  
Removal of oxidized lipids from LDL or cells represents the first step of HDL-
mediated protection from oxidative damage induced by free radicals: 
phospholipid hydroperoxides are rapidly transferred from oxidized LDL to 
HDL; the transfer can occur directly or can be mediated by transfer protein 
CETP and then are removed from HDL by hepatocytes SR-BI uptaking. The 
HDL capacity to remove oxidized phospholipids depends on the surface lipid 
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monolayer fluidity; also this capacity is not specific for LDL but was detected 
also for erythrocytes and astrocytes (61, 62). The accumulation of oxidized 
lipids in HDL likely results not only from their transfer from LDL but also from 
triglyceride-rich remnant particles and endothelial cells (63).  
HDLs are major carriers of plasma lipid hydroperoxides in animal model of 
atherosclerosis (64) and in humans (65). HDLs are also carriers of enzymes 
involved in lipid hydroperoxides destruction (66). The most important is 
paraoxonase-1 (PON-1) (67). A number of medical conditions including 
diabetes mellitus, chronic kidney disease, familial hypercholesterolaemia and 
autoimmune disease are associated with both decreased serum PON1 
activity and increased CVD risk (68). ApoA-I contributes to the antioxidant 
capacity. Its structure in fact creates a perfect site for redox reaction, in 
particularly are involved Met112, Met 148 and Tyr115 residues (69). 
Among other enzymes transported by HDLs, platelet-activating factor acetyl 
hydrolase (70) and LCAT (71) demonstrated anti-inflammatory capacity (71).  
 
Vascular tone 
Endothelial cells produce and release several vasoactive molecules that 
constrict and release the vessel. Among these molecules, nitric oxide (NO) is 
generated by endothelial NO synthase (eNOS), which transcription can be 
reinforce by endothelial insults and biochemical species (e.g. oxidized LDL). 
activates guanylate cyclase in vascular smooth muscles cells and induce 
relaxation. Decrease in NO bioavailability is a key feature in endothelial 
dysfunction. In vivo studies by coronary angiography (72) and intravascular 
ultrasound analysis (73) showed a strong correlation between plasma HDL 
and NO-dependent coronary vasodilation. Moreover, plasma HDL-C 
concentration has been shown to be an independent predictor of NO-
dependent peripheral vasodilation in healthy subjects (74), as well as in 
hyperlipidemic and diabetic patients (75, 76). Strongly supporting these 
observations, intravenous infusion of sHDL in hypercholesterolemic subjects 
restores the endothelial dysfunction by increasing NO bioavailability (77).  In 
vitro studies have shown that incubation of endothelial cells with HDL 
activates eNOS and this is mediated by the interaction of apoA-I with SR-BI 
(78). Subsequent intracellular events culminating in the activation of NO 
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production are mediated by PI3K/Akt signalling pathway and involve 
intracellular calcium mobilization, an increase in intracellular ceramide levels 
and eNOS phosphorylation (78, 79). ApoA-I is necessary, but not sufficient 
for eNOS stimulation, since no activation is observed with lipid free apoA-I.  
Another vasoactive molecule that acts synergistically with NO is prostacyclin 
(PGI2). It is generated from arachidonate derived from phospholipids of cell 
membrane or from exogenous substrate, by action of cycloxygenase (Cox). 
Oxidative stress and other factors can reduce the production of PGI2 causing 
endothelial dysfunction and progression of atherosclerosis. Incubation of 
endothelial cells with HDL causes a dose-dependent increase of PGI2 (80, 
81). HDL cholesteryl esters are the most efficient substrate for PGI2 
production, HDL may act, as for NO release, by interacting with SR-BI (82). 
HDL can also activate a calcium-sensitive membrane bound phospholipase, 
which make endogenous arachidonate available for PGI2 synthesis (83). 
Finally HDL increase cytokine induced expression of Cox-2 enzyme that 
occurs through an NF-kB independent pathway. 
 
Anti-inflammatory effect 
Atherosclerosis is an inflammatory disease and inflammation participates in 
all stages of atherosclerosis. Normal endothelium does not support leukocyte 
recruitment, however injury to vascular endothelium induces the expression 
of selective cell adhesion molecules (CAMs), that recall white blood cells to 
the atherosclerotic lesion (84).  
Vascular cell adhesion molecule-1 (VCAM-1), intercellular adhesion 
molecule-1, E-selectin and P-selectin are the main mediators attracting 
monocytes and other white blood cells to adhere to the endothelial surface 
and transmigrate into the intimal tissue. CAMs are produced in endothelial 
cells by different stimuli, including pro-inflammatory cytokines, as tumor 
necrosis factor-α (TNF- α). HDLs have shown ability in reducing leukocyte 
adhesion (85) through the inhibition of the expression of adhesion molecules, 
as demonstrated in studies in human umbilical vein endothelial cells 
(HUVEC) (86) with a dose dependent effect, that has its maximum at 
physiological HDL concentrations. Interestingly the HDL3 subfraction is more 
effective than the larger HDL2 (86), possibly because of a greater S1P 
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content (87). The inhibitory capacity is largely affected by apolipoprotein and 
phospholipid composition of HDL determining HDL particles shape: spherical 
HDL are more efficient than discoidal particles (86). Lipid composition is also 
important, in particular the length and degree of unsaturation of fatty acid 
residues (86). The anti-inflammatory pathway activated by HDL is not 
completely understood, but there are evidence of signalling perturbation at 
post receptor sites, probably inhibiting NF-κB translocation and DNA binding 
(88, 89). HDL interact with SR-BI through apoA-I and with S1P receptor 
through S1P, then activating an inhibitory PI3K/NOS pathway that eventually 
reduces translocation of NF- κB. Several studies in atherosclerosis-prone 
animal models proved that apoA-I overexpression significantly inhibits CAM 
expression on vascular endothelium and monocyte recruitment (90). The 
infusion of sHDL reduced VCAM-1 and E-Selectin in porcine model of acute 
inflammation (91). In human, low HDL concentrations are associated with 
increased plasma levels of soluble CAMs (49). 
 
Antithrombotic activity 
Platelets are involved in the progression of atherosclerosis because they can 
modify the proprieties of endothelial wall cells secreting growth factors and 
chemokines, and recruiting inflammatory cells (92). Platelets represent the 
key element for the formation of a thrombus formed following the rupture of 
the atherosclerotic plaque. Endothelium-derived NO and PGI2 have a 
antithrombotic effect, inhibiting platelet aggregation, increasing cellular 
content of cGMP and cAMP, respectively. Thus, HDL stimulation of these two 
pathway reduces coagulatory ability. In addition, HDLs are effective in 
limiting, in a dose dependent manner, agonist-induced production of platelet-
activating factor (PAF), a molecule that stimulate platelet aggregation and 
smooth muscle contraction. Moreover, circulating levels of Von Willebrand 
factor (vWF), expressed by endothelial cells and essential for platelet 
adhesion and aggregation is inversely correlated with plasma HDL (93). 
Interestingly, high HDL-C level in humans is associated with a reduced ex-
vivo thrombogenic potential (94) and injection of sHDL in animal model of 
thrombosis reduces thrombus formation (95).  
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HDL decreases platelet aggregation mediated by glycoprotein IIb/IIIa in 
response to thrombin, collagen, ADP and adrenaline (92, 96, 97). 
It has been recently demonstrated that plasma-derived, as well as synthetic 
HDL are able to inhibit tissue factor (TF) expression in endothelial cells and 
monocytes. Only complete HDL are effective, while lipid-free apoA-I does not 
retain this property, since the TF inhibition is dependent on modulation of 
cellular cholesterol content through the interaction with SR-BI. This 
interaction inhibits the activation of p38 MAPK and the repression of the PI3K 
pathway responsible for TF expression (98). 
 
4. Lecithin:cholesterol acyltransferase 
HDL inherited disorders also represent a unique tool to evaluate how specific 
HDL subpopulations are involved in the atheroprotective activity mediated by 
HDL. Genetic LCAT deficiency permits to evaluate a specific HDL 
subpopulation and to assess the relevance of LCAT enzyme in 
atherosclerosis. Carriers of two mutant LCAT alleles have severely low 
plasma HDL-C, apoA-I, and apoA-II levels, associated with alterations in HDL 
structure and particle distribution, with a selective depletion of large particles 
and predominance of small preβ-HDL (18, 99) 
4.1.  LCAT: from the gene to the enzyme  
Human LCAT gene was firstly cloned by McLean in 1986: it was made by 6 
exons and it is ~ 4.4 kB long (100). LCAT is located as a single gene on 
locus 22 of the long arm of chromosome 16 (16q22) (101) and encodes for a 
416-aminoacid glycoprotein preceded by an hydrophobic sequence of 24 
aminoacids, with a  molecular mass of ~ 4.9 kDa (101). The gene is 
expressed mainly in the liver and to a lesser extent in brain and testis (102). 
Very low concentrations are in the cerebrospinal fluid, although its role in this 
compartment is not yet clear (103).  The synthetized protein is secreted in the 
plasma and circulates in a glycosylated form (N-linked and O-linked) for a 
total molecular mass of approximately 67kDa (103). The LCAT protein 
structure is not completely known, although a partial model has been 
proposed, based on its homology with other lipases (104). This model 
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assigned LCAT to the α/β hydrolase fold family, with a central domain 
consisting of seven  β-strands, linked by four α-helices and separated by 
loops. The catalytic triad includes Ser-181, Asp-345 and His-377 (Figure 3), 
together with Phe-103 and Leu-377 that form the oxyanion hole (104). The 
disulfide bridge between Cys50 and Cys74 was proposed as “lid” domain, 
typical of lipases, and it is involved in the substrate recognition and it is 
essential for the binding to lipoprotein surface (103, 105).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Average plasma concentration of LCAT is 5 mg/L and is subjected to little 
variation with age, sex, lifestyle and smoking. LCAT mass correlates with 
enzyme activity either when measured on endogenous substrate (cholesterol 
esterification rate) either on standard exogenous substrate (LCAT activity) 
(106).  
 
4.2. LCAT reaction and substrates 
LCAT was demonstrated to own three different catalytic reaction: 
acyltransferase activity, phospholipase A2 and lysolecithin acil transferase 
(LAT) activity.  
Figure 3. Structure of lecithin:cholesterol acyltransferase 
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The most important physiologic reaction of LCAT is the conversion of 
cholesterol and phosphatidylcholine (PC) (lecithin) to cholesteryl ester and 
lysophosphatidylcholine (lysoPC). As depicted in  
Figure 4, it is a multistep reaction starting with the cleavage of the fatty acid 
in sn-2 position of lecithin and the transfer to Ser181; then the fatty acid is 
transferred to the free 3-β hydroxyl group of cholesterol (transesterification), 
generating cholesteryl ester (CE) (103). LCAT is the unique enzyme in 
plasma able to esterify cholesterol. 
 
 
 
Figure 4. LCAT reaction. Firstly LCAT acts as a phospholipase A2, cleaving 
the sn-2 fatty acid of the phoshatidylcholine (PC) with formation of 
lysophosphatidilcholine (LPC). Then, the fatty acid, bound to Ser181 of LCAT 
is transferred to the free hydroxyl group 
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The preferential substrate of LCAT are small, discoidal and pre-β-migrating 
HDL (α-LCAT activity) (107), although it binds with lesser affinity also apoB-
containing lipoproteins (β-LCAT activity) (108). Measurement of affinity of 
human LCAT for different substrate showed that it was 2.3 to 4-fold higher for 
HDL compared to LDL, with relative reactivity (appVmax/app Km) of 6.5%, 
1.3% and 16% for LDL, HDL2 and HDL3 compared to rHDL (109).  Although 
LCAT can directly esterify the free cholesterol on apoB-containing 
lipoproteins, these latter mainly acquire CE by CETP, which exchanges CE 
(made by LCAT) for TG between HDL and LDL. Either way, LCAT is the -
main source of CE on apoB-containing lipoproteins. Other CE are produced 
by one intracellular enzyme Acyl-CoA:Cholesterol Acyltransferase (ACAT) in 
the liver and intestine when chylomicrons and VLDL are secreted (110). 
Besides PC, LCAT can use other phospholipids containing 18:1 or 18:2 fatty 
acids (111), such as phosphatidylethanolamine (PE), but it has no activity on 
other phospholipids or acyl donors, such as phosphatidylserine or 
diacylglycerol (112). The initial binding of LCAT occurs to the lipid surface, 
followed by a specific activation by apoA-I. Other apolipoproteins (apoE, 
apoA-IV and apoC-1) can activate LCAT, but less effectively than apoA-I 
(113). Among these, apoE represents the cofactor for LCAT activity on apoB-
containing lipoprotein (114). The effect of aminoacid substitution on apoA-I 
demonstrate that three arginine in 149, 153 and 160 are crucial for LCAT 
binding (115). LCAT activation by apolipoproteins and peptides requires lipid 
binding and amphipathic α-helical structures with nonpolar face of 
approximately 100°, a central region of acidic residues opposite to the 
nonpolar face and basic residues distributed at the polar-nonpolar interface. 
Alteration of residues from 143 to 187 makes apoA-I unable to activate the 
enzyme (103). ApoA-II is not able to activate LCAT and may impair the 
activation by apoA-I likely hiding active its sites. The presence of LCAT 
enhance fusion of lipidated apoA-I-only lipoproteins (LpA-I) and apoA-II-only 
particles (LpA-II) (116). In addition the two apolipoproteins may compete for 
binding sites on the PC-cholesterol vesicles (117). Studies on mice have 
shown that cholesterol transferring between preβ-HDL and α-HDL is slower 
in human apoA-I/apoA-II compared to apoA-I transgenic mice and is 
correlating with a more efficient cholesterol efflux in the latter (118). 
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The LAT activity of LCAT allows the reverse reaction of LCAT, which is the 
reacylation of lysophosphatidylcholine into phosphatidylcholine with LDL as a 
substrate (119).  
In addition LCAT can also transesterify and hydrolyze PAF and oxidized PCs 
with shortened chains in the sn-2 position; through these reactions, LCAT 
contributes to the metabolism of oxidized phospholipids in plasma, especially 
those generated during LDL oxidation (120, 121). 
Interestingly, LCAT is also produced in the brain by astrocytes and it is 
responsible of the esterification of FC on the apoA-containing lipoproteins 
derived from glia. This regulates the cerebral spinal fluid (CSF) concentration 
of apoE and apoA-I and affects the maturation of nascent lipoproteins 
derived from the glia (122). 
Several reports have demonstrated that sphingomyelin is an inhibitor of 
LCAT activity. Other inhibitors include: hydroperoxides of PC, generated 
during oxidation of lipoproteins,  PC with trans-fatty acids and chains of C18, 
likely changing the physical properties of the lipid e.i. altering apoA-I 
conformation or charge or competing with PC (103, 123, 124). Mild oxidation 
leads to a reduction in plasma PC and increase in short-chain polar PC and 
inhibition of the transfer of long-chain acyl groups to cholesterol (LCAT 
activity) or to lysoPC (LAT activity), suggesting a possible role of LCAT in 
metabolize oxidized PC (125). 
 
4.3. LCAT is involved in HDL metabolism and reverse 
cholesterol transport 
The interaction between lipid-free or lipid-poor apoA-I and the ABCA1 
transporter on the cell membrane originates a small, discoidal pre-β-HDL, the 
preferred substrate for LCAT, which represents the first step for the efflux of 
cholesterol efflux and phospholipids (107). 
LCAT esterify the FC. CE is more hydrophobic thus it migrates into the 
hydrophobic core of the lipoproteins, leading to the maturation of the HDL 
which becomes spherical and α-migrating (126). The action of CETP and 
various lipases leads to loss of CE from the HDL in exchange of TG. In this 
way α-HDL is converted back into a pre-β-HDL. While pre-β-HDL have a 
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short plasma half-life, since apoA-I is rapidly  removed by the kidney, α-HDL 
have a slower turn over (126). 
Consequently LCAT is involved in HDL metabolism, thus regulating their 
plasma levels.  
LCAT has also long been believed to regulate macrophage reverse 
cholesterol transport (RCT) as proposed by Glomset et al LCAT contributes 
to RCT by maintain cholesterol gradient between the cell membrane and the 
extracellular compartment, promoting passive diffusion of cholesterol (127) or 
via ABCG1 transporter (128). Esterification of cholesterol is also required for 
cholesterol uptake and elimination from the hepatocytes, either through SR-
BI or indirectly through CETP.  
Nevertheless the role of LCAT in RCT is controversial, since there are 
evidences that the conversion of pre-β-HDL into α-HDL depletes the best 
acceptor for cholesterol efflux via ABCA1 transporter, the most important 
actor in cholesterol removal from macrophages (129). Supporting this 
observation, LCAT overexpressing mice show increased HDL-C, but do not 
show increased macrophage RCT (129). Conversely in LCAT-deficient mice, 
RCT occurs despite the lack of LCAT, mostly due to higher levels of pre-β-
HDL and enhanced cholesterol removal by ABCA1 (58). 
 
4.4. Genetic LCAT deficiency 
In 1967 Norum and Gjone described an error in lipid metabolism in a 
Norwegian 33-year-old woman with corneal opacities, proteinuria and 
normochromic anemia (130). Although the renal function  was normal, kidney 
biopsy revealed foam cells in the glomerular tufts. Total serum cholesterol 
was high and almost all was unesterified, accompanied by decrease serum 
lysolecithin and complete absence of HDL on agarose gel electrophoresis. 
Similar phenotype was reported in the proband’s two sisters (131). Lack of 
LCAT was hypothesized and subsequently confirmed by measurement of 
LCAT activity in plasma (131).  
Carriers of LCAT gene mutations showed a wide variety of phenotypic 
presentation. Most homozygous carriers develop corneal opacities and 
hemolytic anemia; chronic and progressing renal insufficiency, often resulting 
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in end-stage renal disease. Heterozygous subjects show a mild phenotype, 
supporting the evidence that LCAT deficiency is an autosomal recessive 
disorder. Loss-of-function mutations in both alleles, depending on the type, 
can lead to two distinct syndromes: familial LCAT deficiency (FLD) and fish 
eye disease (FED). A summary of the clinical and biochemical characteristics 
of these disorders is listed in Table 1 (132). Both are characterized by low 
HDL-c in plasma, but other clinical and biochemical features can be widely 
different (132). While in FLD the lack of LCAT impair the ability of the enzyme 
to esterify cholesterol on both HDL and LDL, in FED the enzymatic activity on 
LDL and VLDL is preserved. The direct consequence is that FLD have a very 
little amount of CE with high FC in all lipoproteins fractions, while FED have a 
subnormal CE/FC with concentration of CE in apoB-containing lipoproteins, 
that are present in normal plasmatic levels (133).  
Among other characteristics, corneal opacity is common in both FLD and 
FED, whereas anaemia, proteinuria and renal disease are clinical features of 
FLD (35). 
The differential diagnosis of FLD and FED in homozygous or compound 
heterozygous can only be made by the measurement of the ability of LCAT to 
esterify the FC on endogenous lipoproteins (α-LCAT plus β-LCAT activity) 
and on synthetic HDL (α-LCAT activity) (99). The classification of 
heterozygous subjects can be made by transient expression of LCAT 
mutants in cultured cells and measurement of LCAT concentration and 
activities in cell media (134). The prevalence of the disease is below 
1:1,000,000 and more than 80 mutations in LCAT gene have been identified 
(132). 
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Table 1. Clinical and biochemical features of FLD and FED. Adapted from 
(132) 
 FLD FED 
Clinical findings   
Corneal opacity ++ + 
Anemia + - 
Nephropathy + - 
   
Routine laboratory   
Triglycerides ↑  
→↑ 
Total cholesterol ↓ → 
LDL-cholesterol ↓ → 
HDL-cholesterol ↓↓ ↓↓ 
VLDL-cholesterol ↓ → 
Hemoglobin ↓ → 
Proteinuria + (in most cases) - 
   
Special laboratory   
Unesterified cholesterol ↑  
→ 
LCAT activity Absent ↓ 
LCAT mass ↓ →↓ 
Renal biopsy Abnormal (in most cases)  
→ 
Cholesterol esterification rate ↓↓  
→ 
Apolipoprotein A-I ↓↓ ↓↓ 
Apolipoprotein A-II ↓ ↓ 
Apolipoprotein E ↑ ↑ 
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Lipoprotein profile 
Lack of LCAT leads to serum lipoproteins abnormalities, mainly characterized 
by very low levels of HDL-C (< 10 md/dL, < 0.26 mmol/L) and reduced apoA-I 
and apoA-II (< 30 mg/dL). Increased percentage of FC is one of the main 
features suggestive of genetic LCAT deficiency. The analysis of HDL 
subclasses in subjects with LCAT deficiency, by bidimensional 
electrophoresis, that separate HDL for surface charge and size, reveals a 
dramatic redistribution of apoA-I-containing-HDL. Homozygous carriers  have 
small, lipid-poor, disc-shaped HDL particles (namely preβ-1 and α-4). 
Triglycerides levels are variable from normal to elevated. FLD subjects show 
a markedly reduced esterified cholesterol in both LDL and HDL fraction, while 
FED have a FC/TC ratio of about 50% compared to control, due to the retain 
of β-LCAT activity. 
Differences between heterozygous carriers and controls are mild, since 
distribution of HDL subpopulations were comparable for size and 
electrophoretic mobility, with a shift toward the smaller HDL particles. Preβ 
were 2-fold increased. In addition heterozygous subjects show a 23% 
increase in  α-4 and a 45% increase in preα-4 levels compared to non-
carriers, whereas the intermediate-sized particle α-3 was similar to that of 
controls (18).  
 
Figure 5. Apolipoprotein A-I (apoA-I)-containing HDL subpopulations of 
representative control, heterozygous, and homozygous LCAT-deficient 
subjects separated by two-dimensional, nondenaturing agarose-PAGE (18). 
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Corneal opacity 
The most peculiar characteristics in FLD and FED patients is the presence of 
corneal opacity that is defined “fish-eye” (Figure 6). It is a gradual process, 
usually appearing in childhood and worsening over years (135). Despite the 
cloudy appearance of the cornea usually patients do not have impaired 
vision, but sometimes they may need corneal transplantation. Analyses of 
LCAT deficient subjects after transplantation revealed that opacity is due to 
FC and PL accumulation in form of 5-200 nm vacuoles, in particular in the 
corneal stroma, with more evident opacity near the limbus, often arranged in 
diffuse, grayish, circular bands (132, 133, 136, 137).  
Linoleic acid (18:2) in predominant in esterify cholesterol fraction in the 
cornea, with a ratio C18:1/18:2 of 1:6.5 (normal ratio in the cornea is 1.4-
4.6:1) (137). 
Other HDL disorders are often associated with morphological and lipid 
composition of the cornea, such as Tangier disease (138), apoA-I deficiency 
(139) and apoA-I/C-III deficiency (4). 
 
 
Figure 6. Slit-lamp photo of patient, showing diffuse bilateral opacity of the 
corneal stroma extending to the limbus, with a peripheral lipoid arc OU (140) 
 
Anemia 
Most FLD patients show mild normochromic anemia associated with 
reticulocytosis. Although anemia has not been described extensively, 
hematological exams showed that red blood cells are characterized by 
increased mean corpuscular volume, heterogeneous shape and peripheral 
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blood smear about 20% of cells are so-called Target cells and/or Knizocytes 
(erythrocyte with aberrant shape characterized by two concavities crossed by 
a thin strip of hemoglobin) (141). 
Analysis of membrane lipids showed changes in composition, with increased 
free cholesterol and phosphatidylcholine with decreased 
phosphatidylethanolamine. Thus altering membrane properties and stability, 
such as fluidity and deformability, which are increased and decreases 
respectively (141).  Radioisotypic studies highlighted reduced erythrocytes 
mean half-life (16-17 days vs 23-35 days of normal subjects (142).  
 
Renal disease 
Glomerulosclerosis represents the most severe consequence of LCAT 
deficiency and is the main cause of morbidity and mortality. Homozygosity 
seems to be a necessary condition for the development of the disease, while 
heterozygous subjects are not affected. Proteinuria is often diagnosed in the 
second or third decade and worsens in the fourth-fifth decade (133, 143) 
although the progression of renal disease is unpredictable, with subjects 
reaching renal failure in their early 20s. 
Glomerulosclerosis is both focal and segmental that becomes global with the 
progression of the disease (144).  
Renal function, measured by serum creatinine or creatinine clearance usually 
remain normal, with a sudden deterioration of renal function with progression 
of renal insufficiency and increase of proteinuria. FLD patients shows varying 
phenotype, depending on diet, abnormal lipoproteins and previous kidney 
disease (144, 145). 
Renal biopsies reveal focal segmental glomerular sclerosis with mesangial 
expansion, mild increase in mesangial cellularity and thickening of the 
glomerular capillary walls (145). Lipid staining by Oil Red O shows lipid 
deposition with vacuolization of the glomerular basement membrane and 
foamy appearance. Increased free cholesterol and phospholipid are found in 
the glomerula (145). 
The pathogenesis of renal disease is not completely understood. In some 
FLD patients oxidized phospholipids accumulation in the glomerula has been 
described (146).  
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It has been proposed that presence of an abnormal lipoprotein, called 
lipoprotein X (LpX) and/or possibly large molecular weight LDL, which 
accumulates in plasma, are involved in glomerulosclerosis development 
(147). The LpX is associated to the fraction of LDL (density 1.019-1.063 
g/mL), that resembles a bilayer vesicle with a diameter of 30-70 nm. It 
contains a high content of free cholesterol (30%) and phospholipids (60%), 
mainly phosphatidylcholine. The core components are cholesteryl esters 
(2%) and triglycerides (2%). The major proteins are albumin, apoC-I, C-II, C-
III and E that are on the surface. LpX is characterized by an opposite 
electrophoretic migration on agarose gel, since it migrates to the cathode and 
not to the anode as the other lipoproteins (148). The residual LCAT activity in 
FED presumably prevent the formation of a significant amount of LpX. These 
particles remain trapped in capillary loops of the glomerulus  and induce 
endothelial and vascular injury (147). However, LpX is not always detected in 
FLD patients with renal disease (143). 
 
4.5. Therapies for LCAT deficiency 
Specific treatment for genetic LCAT deficiency is not currently available, 
probably due to the rareness of the disease. LCAT-deficient carriers are 
candidates for cornea and kidney transplantation, but the disease can 
reoccur in transplanted tissue (149). Therapy is mainly aimed at correcting 
the dyslipidemia and at delaying the evolution of chronic nephropathy, with 
changes in lifestyle an diet, anti-hypertensive treatment to avoid proteinuria 
(145). Combined treatment with nicotinic acid and fenofibrate have 
demonstrated amelioration of lipid profile, a reduction of LpX and proteinuria 
in one FLD carrier (150). Therapy with angiotensin II receptor blockers and 
lipid-lowering drugs showed in a case report study benefit in blood pressure, 
lipid abnormalities, proteinuria and also kidney function, probably delaying 
progression to renal failure (151).  
Successful studies with infusion of normal plasma to correct the biochemical 
LCAT deficient phenotype (152) pave the way for the development of 
enzyme replacement therapy as a therapeutic strategy. Since LCAT has a 
relatively long half-life and does not require any specific tissue delivery, 
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enzyme replacement results feasible. In vitro studies with recombinant 
human LCAT proved efficacy in correct the abnormal lipoproteins observed in 
FLD plasma (153) and in promoting the maturation of immature HDL (154). 
Experiment in mouse model of LCAT deficiency and the first-in-human 
treatment provided encouraging results (153, 155) (156).  
 
4.6. LCAT deficiency and atherosclerosis 
Without LCAT, HDL-C, apoA-I and apoA-II levels are dramatically reduced, 
by lacking of mature HDL and the rapid catabolism of discoidal HDL by the 
kidney (157). Thus, theoretically, cases with LCAT deficiency should be at 
increased risk of cardiovascular disease because of HDL deficiency. More 
than one study supported the evidence that lack of LCAT is not associated 
with increased cardiovascular risk. In one study, two Canadian homozygotes 
and seven heterozygotes with FLD have been followed for 25 years and no 
vascular events were recorded in any carriers aged up to 70 years (158). 
Supporting observations came from another study on a larger number of 
carriers from 13 Italian families, that clearly showed that functional LCAT is 
not required for efficient atheroprotection (25). In this study carriers of LCAT 
deficiency had a 0.07 mm smaller average carotid intima media thickness 
(IMT) and 0.21 mm smaller maximum carotid IMT than controls with a gene-
dose dependent effect (25) (Figure 7). 
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Figure 7. Average IMT (Avg-IMT) and maximum IMT (Max-IMT) values in 
carriers of 1 (n=28) or 2 (n=12) mutant LCAT alleles and in control subjects 
(n=80). IMT measurements were adjusted for age, sex, BMI, smoking status, 
hypertension, family history of cardiovascular disease, ultrasound device, 
and total cholesterol, HDL-C, and triglyceride levels. Data are expressed as 
geometric mean and 95% CIs. P=0.0003 for average IMT and P=0.001 for 
maximum IMT when tested for trend (25). 
 
 
Contrasting results came from other groups, showing increased preclinical 
atherosclerosis in carriers compared to control, although only 2 out of 47 
heterozygous carriers of the study had a premature cardiovascular event 
(159). Supporting the evidence that low LCAT levels are associated with 
increased carotid IMT, carotid magnetic resonance imaging studies were 
conducted in two homozygous and 38 heterozygous carriers. Results clearly 
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showed that LCAT deficient carriers had a greater increase in the thickness 
of carotid artery walls and 32% increase of plaque component compared with 
family controls (160). In the same population, arterial stiffness, an 
independent predictor of cardiovascular events, was also significantly 
increased (161).  
Studies in animal models led to contrasting results, often dependent on the 
species utilized. LCAT overexpression (162-164) or downregulation (165, 
166) in mice failed to demonstrated association with atherosclerosis. The 
increased atherosclerosis found in mice overexpressing LCAT was probably 
due to the accumulation in plasma of dysfunctional large apoE-rich HDL, that 
are defective in the delivery of cholesterol to the liver via SR-BI (164). Mice, 
which do not express CETP, are not protected against diet-induced 
atherosclerosis, while rabbits, which express CETP, show less 
atherosclerosis than control animals. Interestingly double transgenic mice for 
LCAT and CETP develop less atherosclerosis than LCAT-transgenic mice, 
although more than wild-type mice (167). Studies in rabbit gave opposite 
results (168, 169). Recent study in CRISPR/CAS9 mutant LCAT hamsters 
demonstrated that LCAT deficiency in hamsters develops pro-atherogenic 
dyslipidemia and promotes atherosclerotic lesion formation (170). 
Controversial results were also found in humans, summarized in Table 2. In 
general population studies, as the prospective Epic-Norfolk, the correlation 
between plasma LCAT and the development of coronary artery disease was 
investigated, however no association was found (171). The Copenhagen City 
Heart Study, together with The Copenhagen General Population Study, 
enrolled more than 60,000 subjects found an association of the LCAT 
variants S208T with reduction in HDL-C and apoA-I levels, but not with 
increased risk of major coronary events (172). Consistently, no association of 
low plasma LCAT levels with higher carotid intima media thickness in 
secondary prevention subjects (173). In a small study on 74 subjects LCAT 
activity was found to be directly associated with preclinical atherosclerosis in 
metabolic syndrome carriers, as well as in controls (174). Increased LCAT 
activity was associated with formation of small LDL particles, that are more 
atherogenic than large particles, but no data on subclinical atherosclerosis 
was analysed (175). Other studies demonstrated the opposite association in 
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high risk patients (176) as well a positive correlation of LCAT activity with the 
degree of coronary atherosclerosis (177). A very recent report on 267 
patients with angiographically confirmed CAD showed that plasma LCAT 
mass concentration is upregulated and inversely related to plaque volume 
(178). 
 
Table 2. Studies on LCAT and atherosclerosis. Adapted from (179). 
Human studies 
LCAT 
mass/activity 
CAD Reference 
General population 
= Yes (171) 
↓ No (172) 
Subjects at high 
cardiovascular risk 
↓ Yes (176, 180, 181) 
↑ Yes 
(174, 175, 177, 
182) 
↓ No (173) 
 
 
A possible explanation for the contrasting findings about LCAT and 
atherosclerosis have been recently proposed by a study of Our group. The 
development of preclinical atherosclerosis follows a different development in 
partial LCAT deficiency compare with complete LCAT deficiency, since in 
FLD the lack of LCAT affects the ability to esterify free cholesterol on both 
HDL and LDL, reducing the cholesteryl esters in plasma, while in FED, LCAT 
maintain the capacity to generate esters on apolipoprotein B-containing 
lipoproteins  (183).  
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The lecithin:cholesterol acyltransferase (LCAT) is the unique enzyme in human able to 
esterify the free cholesterol in plasma and play an important role in high-density lipoprotein 
(HDL) metabolism. Genetic LCAT deficiency leads to abnormal plasma lipoprotein profile, 
characterized by low HDL-C, mainly small discoidal and immature HDL (preβ-HDL).  
Despite the severely low HDL-C concentrations, LCAT deficiency is not unequivocally 
associated with increased atherosclerosis (179) and it has been often associated with 
atheroprotection (134). Trying to explain this controversy, we hypothesized that HDL in 
carriers of LCAT deficiency were more effective in  atheroprotection. For this purpose we 
defined two aims: 
I) evaluate the ability of HDL in LCAT deficient patients to maintain endothelial cell 
homeostasis 
II) assess the phenotype and function of monocytes in LCAT deficiency 
For both aims, I took advantage of the large availability of plasma samples from LCAT 
deficient patients of Prof. Calabresi’s laboratory at the University of Milan and of Prof. 
Stroes’ laboratory at the Academic Medical Center in Amsterdam.  
For aim (I) HDLs were isolated from plasma of homozygous and heterozygous LCAT 
deficient patients and from control subjects, and tested on endothelial cells (HUVEC) to 
prove their ability to promote nitric oxide production and to inhibit adhesion molecules 
expression. The project was completed with additional analysis to demonstrate the 
structural characteristic in HDL responsible for the increased efficiency of these particles. 
For aim (II) the project was conducted in Amsterdam, in Prof. Stroes’ laboratory where 
monocytes were freshly isolated from a small number of patients selected among carriers 
of LCAT deficiency. Immunophenotype, cytokine production upon stimulation, migratory 
capacity of monocytes were assessed. In addition these monocytes were compared with 
monocytes isolated from carriers of other genetic hypoalphaliproteinemias (ABCA1, 
APOA1 mutations). 
In addition, measurement of flow-mediated vasodilation (FMD) in carriers was used as in 
vivo measurement of endothelial functionality.  
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MATERIALS  
AND METHODS 
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1. SUBJECTS   
11 homozygous, 9 compound heterozygous and 67 heterozygous carriers of LCAT 
deficiency were recruited for the study, for a total of 87 subjects. 41 family members 
accepted to participate as control group. All subjects were recruited among those 
belonging to the Italian LCAT-deficient families (99, 167).  11 homozygotes and 49 
heterozygotes are FLD, remaining are FED.  
The monocyte studies were conducted at the Academic Medisch Centrum of the University 
of Amsterdam on a representative subgroup of carriers of LCAT mutations. 12 carriers of 
genetic LCAT deficiency were selected (7 heterozygotes and 5 homozygotes) and 9 
control subjects matched for age, gender and BMI. For the comparison study, carriers of 
10 ABCA1 and 9 APOA1 mutations were recruited. Exclusion criteria were history of 
cardiovascular diseases, chronic kidney disease, diabetes or any condition associated with 
acute inflammation. Each subject provided written informed consent. The study was 
approved by the local Institutional Review Board and conducted according to the principles 
of the International Conference of Harmonization-Good Clinical Practice guidelines.  
Blood samples for the study on endothelial cells and for lipid profile measurement were 
collected after an overnight fast, centrifuged at 4°C. Aliquots were immediately frozen and 
stored at -80°C until assayed.  
 
2. STUDIES ON ENDOTHELIAL CELLS 
2.1. Plasma lipids and apolipoproteins 
Plasma total cholesterol, HDL-C, triglycerides and apolipoproteins levels were measured 
by automated analyser Roche Diagnostics c311. LDL-C was calculated using Friedewald’s 
formula. The plasma concentrations of HDL containing only apoA-I and particles 
containing both apoA-I and apoA-II were determined by electroimmunodiffusion in agarose 
gel in a slightly alkaline (pH 7.6) buffered solution (Sebia Italia).  
2.2.  HDL purification 
HDLs (d = 1.063-1.21 g/mL) were purified by sequential ultracentrifugation from plasma of 
six homozygotes carrying different LCAT mutations (Thr274-Ile, Arg147-Trp, Lys218-Asn, 
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and Leu372-Arg), 10 heterozygotes carrying six different LCAT mutations 
(Thr274-Ile, Arg147-Trp, Lys218-Asn, delG stop 16, Val309-Met, and delG Thr13-Met), 
and 10 family controls. Since homozygotes have very low plasma HDL concentrations, 
plasma samples were pooled in two preparations of three subjects each before 
ultracentrifugation, to allow enough HDL for the in vitro experiments. KBr salt was used to 
modify density at 1.080 g/mL, then stratified with a KBr solution at the same density and 
ultracentrifuged overnight to obtain separation of HDL from other lipoproteins with smaller 
density. Then density was corrected with KBr salt to 1.21 g/mL and stratified with a same 
density KBr solution, then ultracentrifugated overnight again. Thus, HDL were separated 
from other greater density plasmatic protein and dialyzed against sterilized saline 
immediately before use. HDL protein concentration was determined by Lowry colorimetric 
assay.  
 
2.3. HDL subclasses analysis  
HDLs were separated according to their size by non denaturating gradient gel 
electrophoresis of the d < 1.21 g/mL using precast 4-30% polyacrylamide gels (184).  
Preβ-HDL content was measured after separation by 2D electrophoresis followed by 
immunodetection against human apoA-I and expressed as percentage of total apoA-I 
(184). 
 
2.4. Sphingosine-1-phosphate content 
Shpingosine-1-phosphate (S1P) content on HDLs was assessed by a commercial 
competitive ELISA assay (Echelon Biosciences) and expressed as ρmol/mg of HDL 
protein. The S1P coated 96-well plate was blocked to reduce non-specific binding. The 
S1P standard curve and samples were mixed with the anti-S1P antibody before adding to 
the plate. The anti-S1P antibody bound to the S1P coated plate or the S1P in the sample. 
Following incubation and plate washing, streptavidin-horseradish peroxidase (HRP) was 
added to the plate and bound to all anti-S1P antibodies (labelled with biotin) bound to the 
plate. After an additional incubation and plate washing, tetramethylbenzidine (TMB) 
substrate was added and the colorimetric reaction stopped by the addition of 1N sulfuric 
acid. The absorbance at 450 nm was measured and the concentration of S1P in the 
samples was determined by comparison to the standard curve. 
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2.5.  Measurement of plasma adhesion molecules 
 
Soluble forms of intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion 
molecule-1 (VCAM-1) and E-selectin were measured with commercial ELISA kits (R&D 
Systems). A monoclonal antibody specific for the adhesion molecules were pre-coated 
onto a microplate. Standards, samples, controls were added and any sVCAM1 or sICAM-1 
or sE-Selectin presents were bound by the immobilized antibody and the enzyme-linked 
monoclonal antibody specific for sVCAM1 or sICAM-1 or sE-Selectin. Unbound materials 
were washed away. HRP-conjugate antibody was added and binds to the captured 
analyte. By washing any unbound substances and/or antibody-enzyme reagent was 
removed, thus a substrate solution was added to the wells and blue color develops in 
proportion to the amount of protein bound. The color development was stopped turning the 
color in the wells to yellow and the intensity of the color was measured at 450 nm. 
 
2.6. Reconstituted HDL preparation 
ApoA-I and apoA-II were purified from human plasma, as previously described (185) and 
discoidal reconstituted HDLs (rHDLs) containing apoA-I and POPC (rLpA-I) were prepared 
by the cholate dialysis technique (186). rHDLs containing both apoA-I and apoA-II 
(rLpA-I:A-II) were obtained by incubating rLpA-I with lipid-free apoA-II (apoA-
II:apoA-I = 1:2, w:w),  as previously described (185). rHDLs were then isolated by 
ultracentrifugation (d < 1.21 g/ml) and the presence of apoA-I and apoA-II was verified by 
SDS-PAGE followed by Coomassie blue R250 staining. The size of the particles was 
estimated by gradient gel electrophoresis (186) using the Pharmacia Phast system. 
Phospholipid content of rHDL was determined by an enzymatic method (187), and proteins 
were measured by the method of Lowry et al. (188). 
 
2.7.  Endothelial cells  
All experiments were performed on primary cultures of human umbilical vein endothelial 
cells (Clonetics, Lonza) in M199 with 0.75% BSA and 1% FCS. Plasma HDLs were used 
at protein concentration of 1.0 mg/mL and were sterilized with 0.22 μm filters before use. 
Cells were growth with complete growth media (M199 with 10% serum, 1% L-Glutamine, 
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1% antibiotics, EGF 0.1 ng/ml + FGF 1 ng/ml + ECGF 2 μl/ml) in 12-well plates until 90% 
confluence and starved 18 hours before experiment in M199 with 0.75% BSA, 1% FCS. 
 
2.8. VCAM-1 expression in endothelial cells 
Endothelial cells were incubated overnight with HDL, washed with PBS and then 
stimulated with TNF-α (10 ng/mL) for 8 hours. Then media was collected and cells were 
lysate with lysis buffer containing 20 mM Tris, pH 6.8, 1 mM EDTA, 4% SDS, 20% 
glycerol, 1 mM NaOv, 1 mM NaF, 1 ug/ml leupeptin, 1 mM benzamidin, 10 ug/ml soybean 
trypsin inhibitor, 0.5 mM DTT, 1 mM Pefabloc. VCAM-1 expression in medium was 
measured by commercial matched antibody pairs ELISA kit (BioSource) that employs a 
quantitative sandwich enzyme immunoassay technique and normalized by the protein 
concentration of the total cell lysate. Pre-coated microplate with specific antibody for 
VCAM-1 was used. Standards and samples are pipetted into the wells and any VCAM-1 
present is bound by the immobilized antibody. After removing any unbound substances, a 
biotin-conjugated antibody specific for VCAM-1 was added to the wells. After washing, 
avidin conjugated- HRP was added. Following a wash to remove any unbound avidin-
enzyme reagent, a substrate solution was added and color develops in proportion to the 
amount of VCAM-1 bound in the initial step. The color development is stopped and the 
intensity of the color is measured. 
 
2.9. eNOS expression 
Endothelial cells were incubated overnight with HDL (1.0 mg/mL), washed with PBS and 
lysated with lysis buffer. Expression of eNOS was assessed by SDS-PAGE and 
immunoblotting. Total protein concentration was assayed by micro-BCA method 
(ThermoScientific). 25 μg of total protein for each samples were loaded into 8% SDS-
polyacrylamide gel. The separation takes place on the basis of the effects of molecular 
sieve due to the size of the meshes of the gel. While the smaller proteins can pass through 
easily, the larger particles are slow down by frictional forces. Electrophoresis started at 
60V, so that samples can distributed in stacking gel and once entered into the running gel 
the electrophoresis was raised to 80V. At the end of the electrophoresis the proteins were 
transferred into a nitrocellulose membrane (Schleicher & Schuell) for 1 hour at 180 mA, in 
buffer containing 25 mM Tris, 192 mM glycin and 15% (v/v) methanol. Membranes were 
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immediately saturated with a TBS-T buffer (0,018 M Tris, 0,25 M NaCl, pH 7.4, and 0,1% 
(v/v) Tween 20) containing 5% (w/v) non-fat milk, overnight at 4°C. Membranes were 
developed against total eNOS antibody (BD Biosciences) diluted 1:1000 and incubated 
overnight at 4°C, washed 50 minutes in T-TBS solution, incubated with a secondary 
antibody (Dako) conjugated with HRP for 1 hour at 37°C and washed again 50 minutes in 
T-TBS solution at room temperature. Bands were visualized by enhanced 
chemiluminescence (GE Healthcare Biosciences) and analyzed with a GS-690 Imaging 
Densitometer and Multi-Analyst software (Bio-Rad Laboratories). The membranes were 
stripped with a buffer solution containing 0.2 M Glycin, pH 2.2, SDS 0.1% (w/v) SDS e 1% 
(v/v) Tween 20 and reprobed with an antibody against β-actin (Sigma-Aldrich Chemie) 
diluted 1:2000.   
 
2.10. eNOS activation 
Endothelial cells were incubated 20 minutes with HDL (1.0 mg/ml), washed with PBS and 
lysated with lysis buffer. eNOS activation by phosphorylation was evaluated by SDS-
PAGE and immunoblotting using antibodies against phosphorylated eNOS (Ser1177, Cell 
Signalling Technology) diluted 1:1000 overnight 4°C, stripped and reprobed with an 
antibody against total eNOS with method described previously. 
 
2.11. Nitric oxide production 
Endothelial cells were incubated 30 minutes with HDL (1 mg/ml), washed with PBS and 
incubated 2 hours in dark conditions at room temperature with buffer containing diacetate 
4,5-diaminofluorescein (DAF-2 DA, Sigma-Aldrich Chemie). DAF-2DA is a non-fluorescent 
cell permeable reagent that can measure free NO and nitric oxide synthase (NOS) activity 
in living cells under physiological conditions. Once inside the cell the diacetate groups on 
the DFA-2DA reagent are hydrolyzed by cytosolic esterases thus releasing FAD-2 and 
sequestering the reagent inside the cell. Production of nitric oxide converts the non-
fluorescent dye, DAF-2, to its fluorescent triaole derivative, DAF-2T. Fluorescence 
intensity was detected (λ excitation= 485 nm, λ emission= 530 nm) with a Synergy Multi-
Mode microplate reader equipped with the GEN5 software (BioTek).  After detection, cells 
were lysated with lysis buffer and protein concentration was measured with micro-BCA 
assay. For each sample, fluorescence was normalized by the protein concentration of the 
total cell lysate. 
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2.12. Statistical analysis 
Results are reported as mean ± SD, if not otherwise stated. Variables with non-Gaussian 
distribution are presented as median and interquartile ranges and were log-transformed 
before analysis. The association of biochemical with LCAT genotype was assessed as the 
linear trend versus the number of mutant LCAT alleles and adjusted for age, sex and 
family by covariance analysis. The association of HDL functions with LCAT genotype was 
assessed as the linear trend versus the number of mutant LCAT alleles. Independent 
predictors of HDL functionality were identified by multiple regression with stepwise 
selection of variables. All tests were two-sided and P<0.05 was considered as significant. 
All analyses were performed by using the SAS statistical package v.9.2 (SAS Institute Inc., 
Cary, NC). 
 
 
3. STUDIES ON MONOCYTES 
 
3.1. Plasma lipids and apolipoproteins  
 
Lipid levels were measured using fast protein liquid chromatography (FPLC) (189). 
The system contained a PU-980 ternary pump with an LG-980-02 linear degasser, FP-920 
fluorescence and UV-975 UV/VIS detectors (Jasco, Tokyo, Japan). An extra PU-2080i 
Plus pump (Jasco, Tokyo Japan) was used for in-line cholesterol PAP or Triglyceride 
enzymatic reagent (Roche, Basel, Switzerland) addition at a flowrate of 0.1 ml/min. 
Plasma lipoproteins were separated with a Superose 6 HR 10/30 column (GE Healthcare 
Hoevelaken, The Netherlands) using TBS pH 7.4, as eluent at a flow rate of 0.31 ml/min. 
Quantitative analysis of the chromatograms was carried out with ChromNav 
chromatographic software, version 1.0 (Jasco, Tokyo, Japan). Commercially available lipid 
plasma standards (low, medium and high) were used for quantitative analysis (SKZL, 
Nijmegen, the Netherlands) of the separated lipoprotein fractions.  
Apolipoproteins were measured by automated analyser Roche Diagnostics c311. 
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3.2. Flow cytometry 
 
Blood samples were collected into EDTA-coated Vacutainer® tubes (BD, Plymouth, UK), 
after which 50 μL of whole blood was added to each flow cytometry tube plus the 
requested amounts of each antigen specific mAb were added, according by manufactures.  
The following fluorochrome labeled mAb were used: phycoerythrin-CyChrome7 
(PECyTM7)-anti CD14, allophycocyanin (APC)-Cy7-anti CD16, peridinin-chlorophyll-
protein (PerCP)-Cy5.5-anti HLA-DR, APC-anti CD192 (CCR2), fluorescein isothiocyanate 
(FITC)-anti CD195 (CCR5), PE-anti CD11b, APC-anti CD11c, , APC-anti CD36, APC-anti 
CD29, FITC-anti CD282 (TLR2), PE-anti CD284 (TLR4) [all from BD Biosciences, San 
Josè, CA, USA]; PE-anti CD197 (CCR7) [Biolegend, SanDiego, CA, USA]; PE-anti CD204 
(SR-A) [R&D systems, Abingdon, UK]; Fluorescence was measured with BD Canto II and 
analysed with FlowJo software version 7.6.5 (FlowJo, LLC, Ashland, OR). The expression 
of surface markers was calculated as delta (Δ) median fluorescence intensity (MFI) 
(ΔMFI = MFI surface staining - MFI isotype control). 
 
3.3. Monocyte isolation and stimulation  
 
Buffy coats were obtained from study participants after written informed consent. Venous 
blood was drawn in EDTA-coated Vacutainer® tubes (BD, Plymouth, UK) to prevent 
coagulation. PBMC isolation was performed by diluting whole blood in sterile PBS, after 
density centrifugation over LymphoprepTM  (d=1.077) as described elsewhere (190). 
Shortly, blood was diluted in a 1:1 ratio with PBS plus 2 mM EDTA and therefore added to 
a layer of Lymphoprep (Axis-Shield, Dundee, Scotland). Cells were centrifuged for 20 min 
at 600 g at room temperature with slow acceleration and no brake. After washing twice 
with PBS/2 mM EDTA, cells were counted by a CASY counter (Roche Innovatis, Bielefield, 
Germany). After PBMC isolation, monocytes were selected using human CD14 magnetic 
beads and MACS® cell separation columns according to protocol (Miltenyi, Bergisch 
Gladbach, Germany). Briefly, cells were resuspended in MACS buffer (0.5% BSA in PBS/2 
mM EDTA), CD14 MicroBeads (Miltenyi Biotec, Leiden, The Netherlands), incubated for 
30 min at 4°C. Then cells were washed with MACS buffer and resuspended in MACS 
buffer for CD14 isolation using the MACS separation columns. Monocytes were 
resuspended in Dutch modified RPMI culture medium (Roswell Park Memorial Institute 
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medium; Invitrogen, CA, USA) supplemented with 10μg/ml gentamicin, 10mM Glutamax, 
and 10mM pyruvate) and counted by means of a CASY counter. All experiments were 
performed with freshly isolated circulating monocytes.  
A total of 5*105 monocytes were seeded per well on flat-bottom-96 well plates and 
stimulated for 24 hour with RPMI only as a negative control, 10 ng/mL LPS or 10 μg/mL 
Pam3Cys. Then, plates were centrifuged and supernatants were stored at -20°C until 
cytokine measurement. 
    
3.4. Cytokines measurement 
Cytokine production was determined in supernatants using commercial ELISA kits for 
IL1β, TNFα and IL-1Ra (R&D systems, MN, USA), IL-6, IL-8 and IL-10 (Sanquin, 
Amsterdam, The Netherlands) following the instructions of the manufacturer. MCP-1 
ELISA was performed following the manufacturers’ instructions using antibodies anti-
Human CCL2 Purified (14-7099), antiCCL2 Biotin (13-7096) and Human CCL2 
Recombinant Protein (14-8398), all obtained from eBioscience (CA, USA).  
Plasma cytokines were determined using commercial high sensitive ELISA kits for TNF-α 
(eBioscience, CA, USA) and IL-6 (R&D systems, MN, USA) and MCP-1 as described 
above. hsCRP in plasma was determined using the high sensitive ELISA kit for CRP (R&D 
systems, MN, USA).  
 
3.5. Monocyte transendothelial migration 
To assess adhesive and migratory capacity of monocytes, transendothelial migration 
(TEM) was performed. Human aortic endothelial cells (HAECs) were cultured on a 
fibronectin (FN)-coated glass cover to confluency and stimulated overnight with TNF-α (10 
ng/mL). Monocytes (1*106 cells/mL) were added to the HAECs and incubated for 30 min at 
37°C and 5% CO2, then fixed with 3.7% formaldehyde (Sigma-Aldrich, Zwijndrecht, the 
Netherlands).  Cells were later imaged with a Zeiss Axiovert 200 microscope (Plan-
apochromat 10x/0.45 M27 Zeiss-objective; Carl Zeiss Inc., Jena, Germany) and  analysed 
using Image-J software. Transmigrated monocytes were distinguished from adhered 
monocytes by their transitions from bright to dark morphology and quantified using the cell 
counter plugin on a minimum of 4 acquired images.  
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3.6. RNA isolation and quantitative Real-Time PCR  
Monocytes isolated form patients and controls were lysed in Trizol reagent and stored at -
80°C. Total RNA purification was performed according to the manufacturer’s instructions 
(PreAnalytiX GmbH, Switzerland). RNA concentrations were measured using NanoDrop 
software, and isolated RNA was reverse-transcribed using the iScript cDNA Synthesis Kit 
(Bio-rad, Hercules, CA). qPCR was performed using the SYBR Green method (Applied 
Biosciences, Carlsbad, CA). Used primers are listed below in Table 3 (Biolegio, Malden, 
The Netherlands). Samples were analyzed using the ΔCt method, and HPRT was used as 
a housekeeping gene. 
 
Table 3. Primer sequences used for qRT-PCR analysis (5'-3') 
Gene Forward primer Reverse primer 
HPRT CCTGGCGTCGTGATTAGTGAT AGACGTTCAGTCCTGTCCATAA 
TNF-α CCTCTCTCTAATCAGCCCTCTG GAGGACCTGGGAGTAGATGAG 
IL-6 AACCTGAACCTTCCAAAGATGG TCTGGCTTGTTCCTCACTACT 
IL-1β CAGCTACGAATCTCCGACCAC GGCAGGGAACCAGCATCTTC 
MCP-1 CCAGTCACCTGCTGTTATAAC TGGAATCCTGAACCCACTTCT 
CD11c CGTTCGACACATCCGTGTA TTTGCCTCCTCCATCATTTC 
IL-18 ATGCACTGGGAGACAATTCC CTCCCTCCACCTTCTTCCTC 
IL-10 GCCTAACATGCTTCGAGATC TGATGTCTGGGTCTTGGTTC 
CD36 CTTTGGCTTAATGAGACTGGGAC GCAACAAACATCACCACACCA 
SR-A CCAGGTCCAATAGGTCCTCC CTGGCCTTCCGGCATATCC 
ABCA1 GGTGATGTTTCTGACCAATGTGA TGTCCTCATACCAGTTGAGAGAC 
ABCG1 CGGAGCCCAAGTCGGTGTG TTTCAGATGTCCATTCAGCAGGTC 
HMGCoAR CAGGATGCAGCACAGAATGT CTTTGCATGCTCCTTGAACA 
 
3.7. Statistical analysis  
To examine the difference in monocyte phenotype and function between subjects with 
genetic mutation affecting HDL-C concentration (LCAT deficiency) and controls, we 
performed the Student t test or Mann-Whitney U test for normal and non-normal distributed 
variables, respectively. Normality was examined by Shapiro-Wilk test. Variances in both 
groups were examined and tested for similarity with the Levene’s test for variance.  
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Differences between the different genotypes (ABCA1 and APOA1) were analysed with 
one-way ANOVA followed by Tukey’s or Bonferroni’s multiple comparisons test or Kruskal-
Wallis followed by Dunn’s multiple comparisons test. Correlations between HDL-C, apoA-I 
and mRNA expression of inflammatory cytokines were assessed by Spearman’s rank 
correlation. A 2-sided value of P<0.05 was considered statistically significant. All data were 
analyzed with SPSS version 24.0 (SPSS Inc., Chicago, IL, USA Software, La Jolla, CA). 
 
4. In vivo assessment of vascular structure and function   
4.1. Flow-mediated vasodilation 
Evaluations were performed at fasting, between 8.30 am and 10.30 am to exclude 
circadian variations, abstaining from physical activity and smoking since midnight. 
Ultrasonic scans were performed in a quiet temperature-controlled (22±2°C) room by using 
a B-mode ultrasound device (ESAOTE AU4) equipped with a 7.5–10.0 MHz linear array 
transducer, held throughout the scan at the same point of the brachial artery (BA) of the 
non-dominant arm using a stereotactic device. The ultrasonic device was gated to the 
peak R-wave on ECG and images were collected during the end-diastolic phase of each 
cardiac cycle and recorded on SVHS videotapes for off-line measurements. Images of the 
BA were continuously recorded: (i) for 1 min at rest, (ii) during 5 min of low-flow obtained 
by inflating a pneumatic tourniquet placed in the forearm to a pressure 30–50 mmHg 
above the individual systolic blood pressure and (iii) for 3 min after cuff deflation (i.e. 
during the reactive hyperemic phase). In each patient, the BA diameter (BAD) was 
measured using dedicated software, which allows the automatic and continuous detection 
of the distance between the media–adventitia interfaces of the near and far wall of the 
vessel. BAD at rest was the average of the sixty BAD values obtained throughout the pre-
ischemic phase. BAD max was the highest BAD value in the hyperemic phase. FMD was 
calculated as the percentage change between BAD at rest and BAD max. 
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4.2. Carotid intima media thickness  
 
The extent of preclinical atherosclerosis was determined in all available subjects by 
measuring carotid intima-media thickness (IMT) by non-invasive B-mode ultrasonography 
as previously described (25). High resolution B-mode ultrasonography of carotid IMT with 
a linear ultrasound probe (4.0 – 13.0 MHz frequency,14x48 mm footprint, 38 mm field of 
view; Vivid S5 GE Healthcare ®, Wauwatosa, WI, USA) was performed by a single 
sonographer blinded to subject's identity. The IMT was assessed at the far wall distance 
between the interface of the lumen and intima and the interface between the media and 
adventitia in a standardized number of points. The maximal IMT was recorded and 
averaged for the left and right sides of the common carotid artery (30 mm proximal to the 
carotid bulb). Presence of extra-cardiac atherosclerotic vascular involvement was 
determined with presence of focal plaques (> 1.3 mm in longitudinal resolution, lateral or 
medial angle) and/or diffusive mean IMT > 1.3 mm  (> 1.3 mm in longitudinal resolution,   
lateral or medial angle).
~ 49 ~ 
 
 
 
 
 
RESULTS
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1.  SUBJECTS 
In Table 4 are reported the clinical and biochemical characteristics of the Italian and Dutch 
subjects included in the study. As expected total cholesterol, HDL-C, apoA-I and apoA-II 
were lower in carriers of LCAT mutations compared to controls. The effect was gene-dose 
dependent, with heterozygous subjects showing an intermediate phenotype.  
 
Table 4. Clinical and biochemical characteristics of carriers of LCAT gene mutations and 
controls 
 
Carriers of 
two mutant 
LCAT alleles 
Carriers of 
one mutant 
LCAT allele 
Controls PTrend
* 
PAnova 
n 20 67 41   
Age (years) 44.1 ± 4.1 48.4 ± 2.5 45.4 ± 3.2 0.687 0.611 
Gender 
(male/female) 
15/5 43/24 16/25 0.025 0.009 
BMI (Kg/m2) 24.1 ± 0.72 25.1 ± 4.7   24.4 ± 3.3 0.575 0.593 
TC (mg/dL) 158.2 ± 18.0 168.9 ± 5.1 196.4 ± 6.0 0.019 0.001 
LDL-C (mg/dL) 104.1 ± 14.4 101.3 ± 4.8 113.6 ± 5.0 0.746 0.145 
HDL-C (mg/dL) 10.9 ± 1.6 41.6 ± 1.9 60.6 ± 2.3 <0.0001 <0.0001 
Triglycerides (mg/dL) 176.7 (116-372) 112.0 (86-159) 91 (67-121) <0.0001 <0.0001 
ApoA-I (mg/dL) 44.6 ± 5.1 103.8 ± 3.2 127.8 ± 4.3 <0.0001 <0.0001 
ApoA-II (mg/dL) 9.6 ± 1.5 29.0 ± 0.8 33.9 ± 1.3 <0.0001 <0.0001 
ApoB (mg/dL) 81.3 ± 12.7 93.4 ± 3.2 89.8 ± 3.4 0.124 0.068 
Glucose (mg/dL) 105.5 ± 10.5 101.8 ± 7.3 88.8 ± 2.4 0.359 0.437 
Hypertension (n,%) 6 (30) 10 (14.9) 3 (7.3) 0.064 0.085 
Diabetes (n,%) 2 (10) 2 (3) 2 (4.9) 0.251 0.593 
Smoking (n,%) 7 (35) 13 (19.4) 7 (17.1) 0.756 0.359 
Statin treatment 
(n,%) 
6 (30) 4 (6.0) 1 (2.4) 0.001 0.003 
Familial history of 
CVD (n, %) 
12 (60) 31 (46.3) 16 (39.0) 0.494 0.996 
Premature CVD 
(n,%) 
0 (0) 1 (1.5) 1 (2.4) 0.895 0.770 
Renal disease (n,%) 9 (45) 11 (16.4) 0 (0) <0.0001 0.000 
      
Data are expressed as mean ± SEM for all variables, except for triglycerides that are 
expressed as median and interquartile range. Categorical variables are expressed as 
number, percentage* P adjusted for age, gender, and family, except for age. Age was 
adjusted for gender and family; gender was adjusted for age and family.  
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Plasma apoB was also reduced compared to the unaffected family members, although not 
significantly. Risk factors for cardiovascular disease were comparable between carriers 
and controls, but the presence of renal disease was predictably higher when LCAT gene is 
mutated. Renal disease was diagnosed by kidney biopsy or proteinuria or eGFR 
calculation.  
 
Besides the drastic reduction in HDL-C levels, also HDL subclass distribution appears 
highly modified in carriers of LCAT deficiency. Lipoproteins containing only apoA-I (LpA-I) 
and lipoproteins containing both apoA-I and apoA-II (LpA-I:A-II) concentrations were both 
reduced in carriers, with a gene dose effect, but notably the decrease in LpA-I:A-II 
particles was much greater (-72% and -30% in homozygotes and heterozygotes 
respectively) than the decrease in LpA-I (-50% and -18% in homozygotes and 
heterozygotes respectively). Homozygous carriers displayed a higher content of immature, 
discoidal HDL, namely preβ-HDL, versus controls (Figure 8). Furthermore, among 
spherical HDL, HDL3 were smaller in homozygous carriers, who completely lack of the 
largest HDL subpopulations, i.e. HDL2. Heterozygous carriers instead showed a normal 
HDL distribution, with HDL of normal size (Table 5).  
 
 
Table 5. Plasma HDL subpopulations in carriers of LCAT gene mutations 
 
Carriers of 
two mutant 
LCAT alleles 
Carriers of 
one mutant 
LCAT allele 
Controls PTrend
* 
PAnova 
LpA-I (mg/dL) 28.0 ± 4.2 46.3 ± 1.7 56.4 ± 2.5 <0.0001 <0.0001 
LpA-I:A-II (mg/dL) 22.5 ± 4.3 55.8 ± 2.4 79.8 ± 3.8 <0.0001 <0.0001 
Preβ-HDL (% of apoA-I) 40.0 (23.0-49.0) 16.0 (11.8-22.0) 12.8 (10.9-14.1) <0.0001 <0.0001 
HDL2 size (nm) ND 11.2 ± 0.1 11.1 ± 0.1 0.15 0.35 
HDL3 size (nm) 7.4 (7.2-7.7) 9.0 (8.8-9.3) 9.0 (8.8-9.0) <0.0001 <0.0001 
Data are expressed as mean ± SEM for all variables, except for preβ HDL and HDL3 size 
that are expressed as median and interquartile range. ND not detectable.* P adjusted for 
age, gender, and family.  
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Figure 8. HDL subclasses displayed through 2-dimensional electrophoresis of 
homozygotes for LCAT deficiency, heterozygotes and controls 
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2. STUDIES ON ENDOTHELIAL CELLS 
2.1. Characteristics of study subjects 
Seventy-five carriers of LCAT gene mutations participated in the study on endothelial cells. 
Clinical and biochemical characteristics of this group essentially recapitulated the 
characteristics of the total populations, summarized in Table 6.  
 
Table 6. Plasma lipid/lipoprotein levels in carriers of LCAT gene mutations included for the 
study on endothelial cells 
 
Carriers of 
two mutant 
LCAT alleles 
Carriers of 
one mutant 
LCAT allele 
Controls PTrend
* 
PAnova 
n 15 60 32   
Age (years) 44.1 ± 4.9 48.7 ± 2.7 46.6 ± 3.6 0.86 0.73 
Gender(male/female) 14/1 39/21 11/21 <0.001 0.0003 
TC (mg/dL) 159.6 ± 22.9 166.5 ± 5.5 193.0 ± 6.5 0.015 0.03 
LDL-C (mg/dL) 98.5 ± 17.6 97.2 ± 5.0 111.4 ± 5.5 0.21 0.30 
HDL-C (mg/dL) 12.1 ± 2.0 41.9 ± 2.1 59.8 ± 2.3 <0.0001 <0.0001 
Triglycerides (mg/dL) 180 (114-387) 110.5 (81-155) 77.5 (62-113) 0.0002 <0.0001 
ApoA-I (mg/dL) 50.5 ± 5.7 102.1 ± 3.0 136.3 ± 4.6 <0.0001 <0.0001 
ApoA-II (mg/dL) 9.6 ± 1.5 29.0 ± 0.8 33.9 ± 1.3 <0.0001 <0.0001 
ApoB (mg/dL) 67.8 ± 13.0 92.2 ± 3.5 88.6 ± 3.9 0.16 0.03 
Data are expressed as mean ± SEM for all variables, except for triglycerides that are 
expressed as median and interquartile range. Categorical variables are expressed as 
number, percentage* P adjusted for age, gender, and family, except for age. Age was 
adjusted for gender and family; gender was adjusted for age and family.  
 
 
2.2. HDLs ability to modulate NO production in endothelial cells 
To assess if changes in HDL subclass distribution can affect HDL vasoprotective 
properties, anti-inflammatory and NO-promoting activities mediated by isolated HDL were 
tested in endothelial cells. The effect of HDL in modulation of endothelial production of 
nitric oxide (NO) was tested in vitro in HUVEC after incubation overnight with HDLs. As 
shown in Figure 9 (Panel A) HDLs isolated from carriers and controls displayed a 
comparable ability in inducing eNOS expression, with a small decrease in subjects with 
two mutated alleles (PAnova= 0.115). However when tested for their ability to activate eNOS 
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by phosphorylation, HDLs of LCAT deficient subjects proved to be more effective with a 
gene dose dependent effect (Figure 9, Panel B). Consequently, the total NO production 
was higher when endothelial cells were incubated with HDL isolated from carriers 
compared to those of controls (P<0.001). As previously, the induction was gene dose 
dependent (Figure 10). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. eNOS expression (Panel A) and activation (Panel B) induced by HDLs in 
endothelial cells. Data are expressed as fold of increase in HDL-treated vs untreated cells. 
Data are expressed as mean ± SD; n=10 controls, n=10 for heterozygotes and n=6 for 
homozygotes (pooled in two preparations).  
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Figure 10. NO production by HDL. Data are expressed as fold of increase in HDL-treated 
vs untreated cells; n=10 controls, n=10 for heterozygotes and n=6 for homozygotes 
(pooled in two preparations). 
 
Sphingosine-1-Phospate (S1P) is a bioactive lipid, playing a key role in vascular biology 
(191) that circulates bound to HDL via apoM. It is mainly associates with small, dense HDL 
consistently with the high content of apoM (47). S1P binds the S1P3 receptor, expressed 
in endothelial cells (79) and modulate the activity of eNOS through phosphorylation 
operated by Akt (192). S1P concentration in isolated HDL from LCAT deficient carriers and 
controls was measured to assess whether the ability of HDL in LCAT deficiency to activate 
eNOS was dependent on S1P content. As represented in Figure 11, S1P content in HDL 
in homozygous carriers was comparable to that of controls, while heterozygous subjects 
showed a slightly higher content of S1P in HDL.  
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Figure 11. S1P content in HDL. Data are expressed as mean ± SD; n=9 controls, n=9 for 
heterozygotes and n=3 for homozygotes. 
 
 
2.3. Inhibition of VCAM-1 expression by HDLs in endothelial cells 
As the stimulatory effect of HDLs on endothelial NO production is critical for their anti-
inflammatory activity on endothelium (193), the in vitro effect of HDL isolated from carriers 
on the expression of endothelial adhesion molecules after stimulation by TNFα was 
assessed. As expected, HDLs from LCAT deficient patients were more effective in 
inhibiting VCAM-1 expression compared to HDLs isolated from controls. In particular HDL 
from heterozygotes reduced VCAM-1 by 53.1 ± 7.2%, from homozygotes by 65.0 ± 8.6% 
vs 44.4 ± 4.1% in controls (Figure 12).   
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Figure 12. Inhibition of VCAM-1 expression by HDL. Data are expressed as percentage of 
VCAM-1 concentration in media after TNFα-stimulated cells ± SD; n=10 controls, n=10 
heterozygotes and n=6 homozygotes (pooled in two preparations). 
 
2.4. Circulating levels of sCAMs 
As markers of systemic inflammation VCAM-1, ICAM-1 and E-Selectin were measured in 
plasma of LCAT deficient patients and controls. Consistently with the in vitro data, no 
differences were found between carriers and controls when values were tested for trend 
(Figure 13). Levels of sVCAM-1 were significantly higher in homozygotes compared to 
controls and this was possibly attributable to the presence of renal disease in 9 out of 15 
carriers of two mutated alleles (943.5 ± 395.7 ng/mL vs 761.1 ± 394.5 ng/mL, P=0.397). 
Conversely, stratifying for the presence of renal disease, homozygotes did not show a 
significant increase of sICAM-1 levels and sE-selectin concentrations were even lower 
(P=0.026). 
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Figure 13. Plasma levels of soluble CAMs in carriers of two or one mutated LCAT alleles 
and controls. Data are expressed as mean ± SEM; n=32 controls, n=62 heterozygotes and 
n=15 homozygous. P for trend adjusted for age and gender are reported 
 
2.5. Nitric oxide production induced by rLpA-I and rLpA-I:A-II in 
endothelial cells 
Notably, among HDL-related parameters, only LpA-I:A-II levels were independently 
correlated of HDL-induced eNOS activation (β = -0.017 ± 0.006, P=0.007). Thus we tested 
the hypothesis that the selective depletion in LpA-I:A-II, typically observed in LCAT 
deficiency carriers, could account for the increased endothelial protection exerted by HDL. 
For this purpose rHDLs containing only apoA-I or rHDLs containing both apoA-I and apoA-
II were prepared and characterized. Properties of rHDLs are summarized in  
Table 7 and Figure 14. 
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Table 7. Properties of reconstituted HDL 
Particle Size POPC:Protein Molecules/particles 
   ApoA-I ApoA-II 
 nm w/w   
rLpA-I 9.7 2.0:1 2 - 
rLpA-I:A-II 9.8 1.7:1 1 2 
 
 
 
 
 
 
Figure 14. Characterization of rLpA-I and rLpA-I:A-II particles. Particle size by native GGE 
(Panel A) and protein composition by Coomassie-stained SDS-PAGE (Panel B) (194). 
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When endothelial cells were incubated with rLpA-I the NO production was higher than in 
cells incubated with rLpA-I:A-II at all concentrations tested, as presented in Figure 15. 
LpA-I:A-II failed to stimulate NO production or even, at lower concentrations seems to 
have a detrimental effect, although not significant. Consistently with the previous results, 
eNOS activation by phosphorylation was more effective when only apoA-I was present 
(Figure 16, Panel A), although the total eNOS protein abundance was comparable (Figure 
16, Panel B). In addition, inhibition of VCAM-1 expression in TNFα-stimulated cells were 
similarly effective (Figure 16, Panel C). 
 
 
 
Figure 15. NO production in endothelial cells incubated with rLpA-I and rLpA-I:A-II. Data 
are expressed as fold of increase in treated versus untreated cells, n=3. *P < 0.05 versus 
rLpA-I:A-II at the same concentration 
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Figure 16. Effects of rLpA-I and rLpA-I:A-II on eNOS expression (Panel A), NO production 
(Panel B) and TNFα-induced VCAM-1 expression (Panel C) in endothelial cells. Values 
are expressed as fold of increase in treated versus untreated cells, n=3. 
 
To confirm these findings, when rLpA-I:A-II were added to HDLs of carriers to restore the 
LpA-I/LpA-I:A-II ratio observed in controls (HDL/rLpA-I:LpA-I:A-II weight ratio 3:1), the 
ability to promote NO production by endothelial cells was impaired (Figure 17). 
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Figure 17. NO production in endothelial cells incubated with HDLs from heterozygous 
and  homozygous patients before and after supplementation with rLpA-I:A-II. Data are 
expressed as fold of increase in  HDL-treated versus untreated cells; n = 3 for 
heterozygotes 
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3. STUDIES ON MONOCYTES 
3.1. Characteristics of study subjects 
For the monocyte studies we included 12 genetic LCAT deficiency carriers (LCAT-def) 
were representative of the study population and 9 control subjects matched for age, 
gender and BMI. Inclusion criteria were absence of cardiovascular disease, renal disease 
and diabetes at the time of recruitment, as well as absence of any acute inflammatory 
condition. An overview of their clinical and biochemical characteristics are listed in  
Table 8. As expected LCAT-def had lower HDL-C and apoA-I levels (P<0.0001), while 
they showed comparable levels of total cholesterol, triglycerides and LDL-C. Circulating 
hsCRP and other cytokines were measured, but any significant difference was found in 
carriers compared to controls, as reported in Table 9. Hence, no clue of chronic/acute 
inflammatory was detected.  
 
Table 8. Clinical characteristics of carriers of LCAT deficiency and control subjects 
 LCAT-def Controls P-value 
n 12 9  
Age (years) 45.5 ± 4.8 41.2 ± 4.0 0.519 
Gender (male/female) 5/7 5/4 0.670 
BMI (kg/m2) 25.9 ± 1.1 24.5 ± 1.3 0.416 
Smoking (n,%) 3 (25) 5 (44) 0.319 
TC (mg/dL) 174.6 ± 12.7 208.5 ± 9.6 0.060 
TG (mg/dL) 157 (102-213) 113 (93-128) 0.095 
LDL-C (mg/dL) 128.7 ± 11.0 121.5 ± 7.7 0.621 
HDL-C (mg/dL) 26.0 ± 5.0 63.4 ± 5.9 <0.0001 
ApoA-I (mg/dL) 63.1 ± 9.8 121.1 ± 7.9 <0.0001 
ApoB (mg/dL) 109.0 ± 9.7 93.9 ± 2.9 0.247 
Glucose (mg/dL) 82.1 ± 4.3 87.1 ± 4.2 0.420 
Statin treatment (n,%) 5 (42) 1 (11) 0.178 
 
Data are expressed as mean ± SEM for all variables, for triglycerides data are expressed 
as median and interquartile range. Categorical variables are expressed as number and 
percentage. 
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Table 9. Plasma levels of hsCRP and cytokines in carriers of LCAT deficiency and 
controls subjects 
 LCAT-def Controls 
P-
value 
hsCRP (mg/L) 2.5 (2.0-5.2) 1.5 (0.8-3.4) 0.210 
MCP-1 (ρg/mL) 51.3 (38.6-72.1) 74.4 (32.5-101.5) 0.831 
TNFα (ρg/mL) 1.6 (1.3-2.2) 1.8 (1.5-2.3) 0.188 
IL-6 (ρg/mL) 1.6 (1.3-2.2) 1.2 (0.8-1.6) 0.136 
Data are expressed as median and interquartile range for all variables. 
 
 
3.2. Monocyte subset distribution 
Blood monocytes from LCAT deficient carriers and controls were gated based on their 
CD14 and CD16 expression to analyse their subset distribution. CD14++/CD16- 
corresponds to the “classical” subset which displays phagocytic activities, while 
CD14+/CD16+ corresponds to the “intermediate” inflammatory subset. CD14+/CD16++ (“non 
classical” monocytes) are the patrolling subset of monocytes (Figure 18). Subset 
distribution was comparable between carriers of LCAT deficiency and controls. Non 
classical monocytes were slightly decrease compared to controls, although not 
significantly (5.1 ± 0.76 vs 8.1 ± 1.4, P= 0.058) (Figure 19). 
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Figure 18. Gating strategy to study monocyte surface expression. CD14+ and/or CD16+ 
cells were gated, and only HLA-DR positive cells were considered to be monocytes  
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Figure 19. Percentage of monocyte subsets (classical (CD14 ++/CD16-), intermediate 
(CD14+/CD16+), or non-classical (CD14+/CD16+) in carriers of LCAT deficiency (n = 12, 
filled circles) vs. controls (n = 9, open circles). 
 
3.3. Monocyte immunophenotype 
 
Figure 20. Chemokine, adhesion and transmigration markers on total monocytes as 
assessed with flow cytometry in carriers of LCAT deficiency (n=12, black bars) compared 
to controls (n=9, white bars). Bar graphs display the expression (quantified as delta MFI). 
Data are expressed as media ± SEM. *P < 0.05 
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Expression of chemokine, adhesion and transmigration markers on blood monocytes was 
comparable between carriers and controls, with the exception of the integrin CD11c that 
was nearly half in mutations of LCAT gene (ΔMFI 220±56 vs 415±38 P=0.042) (Figure 20). 
Decreased CD11c expression was recapitulated in all monocyte subsets (Figure 21).  
 
 
Figure 21. CD11c expression according to monocyte subset as assessed with flow 
cytometry in carriers of LCAT deficiency (n=12, black bars) compared to controls (n=9, 
white bars). Bar graphs display the expression (quantified as delta MFI). Data are 
expressed as media ± SEM.  
 
Interestingly, the reduction of CD11c was gene-dose dependent as shown in Figure 22. 
The same effect was detected in all monocyte subsets, with the exclusion of the “non 
classical” one (Figure 23). 
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Figure 22.  CD11c expression according to mutant LCAT alleles as assessed with flow 
cytometry; n=9 controls, n=7 for heterozygotes and n=5 for homozygotes. Bar graphs 
display the expression (quantified as delta MFI). Data are expressed as media ± SEM.  
 
Figure 23. CD11 expression in different monocyte subset as assessed with flow cytometry 
in carriers of two mutant LCAT allele (n=5), one mutant LCAT allele (n=7) compared to 
controls (n=9). Bar graphs display the expression (quantified as delta MFI). Data are 
expressed as media ± SEM.  
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CD11c expression on monocytes was found to positively correlate with plasma HDL-C 
levels (r=0.455,P=0.038) but this association was lost when subjects were stratified from 
the presence or absence of LCAT mutation (Figure 24), thus confirming the different 
properties of HDL in LCAT deficiency.  
 
 
Figure 24. Correlation between HDL-C and CD11c expression on monocytes of study 
subjects (n=21) 
 
3.4. Expression of cholesterol uptake and activation markers on 
monocytes 
By flow cytometry expression of markers of cholesterol uptake on monocytes was 
assessed. No difference was found between carriers and controls in the expression of 
scavenger receptor class A (SRA) and CD36 (Figure 25). Moreover, activation marker 
expression, i.e.  toll-like receptors (TLR) was found to be similar (Figure 26). 
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Figure 25. Scavenger receptor expression on total monocytes as assessed with flow 
cytometry in carriers of LCAT deficiency (n=12, white bars) compared to controls (n=9, 
black bars). Bar graphs display the expression (quantified as delta MFI). Data are 
expressed as media ± SEM.  
 
Figure 26. Activation markers expression on total monocytes as assessed with flow 
cytometry in carriers of LCAT deficiency (n=12, black bars) compared to controls (n=9, 
white bars). Bar graphs display the expression (quantified as delta MFI). Data are 
expressed as media ± SEM. 
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3.5. Monocyte transendothelial migration 
Since CD11c is involved in adhesion and migration of monocytes to the vessel wall, we 
aimed to address functional significance of reduced CD11c expression, by measuring ex 
vivo TEM rate of monocytes isolated from carriers and controls. Monocyte migration rate 
directly correlates with the expression of CD11c (r=0.725, P=0.008) in LCAT-def patients 
(but also in the total population, P<0.001, data not shown)(Figure 27). In accordance, we 
observed a consistent reduction in monocyte migration in LCAT deficient carriers 
compared with control subjects (P=0.006), as depicted in Figure 28. Also in this case the 
effect was gene-dose dependent, with carriers of two mutant LCAT alleles showing the 
lowest migratory capacity (PTrend = 0.022, Figure 29).  
 
 
 
 
Figure 27. Correlation between CD11c expression and monocyte migration rate in LCAT 
deficient subjects. 
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Figure 28. Transendothelial migratory capacity of monocytes isolated from carriers of 
LCAT mutation (n=12, filled circles) compared to controls (n=9, open circles). Data are 
presented as percentage of transmigrated cells/total monocytes per field of view. 
 
 
 
Figure 29. Transendothelial migratory capacity of monocytes according to the number of 
mutant LCAT alleles. Two mutant LCAT allele (n=5, filled circles), one mutant LCAT allele 
(n=7, open black circles) compared to controls (n=5, grey open circles). Data are 
presented as percentage of transmigrated cells/monocytes in field of view 
 
~ 73 ~ 
 
3.6. Monocytes challenge with Toll-like receptor ligands 
To assess whether isolated monocytes from patient with genetic LCAT mutations have an 
enhanced inflammatory response, we performed a challenge assay using TLR ligands and 
then we measured the cytokine production in the supernatant. Cells were stimulated ex 
vivo for 24 hours with TLR4 ligand lipopolysaccharide (LPS). Although a trend was 
observed, only interleukin 8 (IL-8) production was significantly lower in carriers compared 
to controls (P=0.027) (Figure 30). Upon stimulation with a TLR2 ligand (Pam3Cys) 
monocytes from LCAT deficient patients produced comparable levels of cytokines, with the 
exception of interleukin-1 beta (IL-1β) that was decreased compared to controls with a 
borderline significance (P=0.051) (Figure 30). Interestingly, unstimulated monocytes (only 
RPMI) showed a lower production of monocyte chemo-attractant protein 1 (MCP-1) 
compared to controls (P=0.018) (Figure 30).  
In order to evaluate whether these reduced Pam3Cys-induced production of IL-1β and 
LPS-induced production of IL-8 were gene-dose dependent, we stratified for the number of 
alleles. As depicted in Figure 32 there was a significant gene-dose effect in the production 
of IL-1β (A), while this effect was not seen in IL-8 production after LPS stimuli (B). A strong 
inverse correlation was seen between the number of mutant LCAT alleles and the baseline 
concentration of MCP-1 (C). 
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Figure 30. Pro-inflammatory cytokine production in response to a 24-hour challenge with 
LPS and Pam3Cys (10 μg/mL) in monocytes isolated from LCAT deficient subjects (n=12, 
black bars) and controls (n=9, white bars). Data are expressed as mean ± SEM.  
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Figure 31. Anti-inflammatory cytokine production in response to a 24-hour challenge with 
LPS and Pam3Cys (10 μg/mL) in monocytes isolated from LCAT deficient subjects (n=12, 
black bars) and controls (n=9, white bars). Data are expressed as mean ± SEM.  
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Figure 32. Gene dose effect in reduction of IL-1β production after Pam3Cys stimuli (10 
μg/mL) (A), IL-8 after LPS stimuli (10 μg/mL) (B) and MCP-1 production in unstimulated 
cells (C). Two mutant LCAT allele (n=5, black bars), one mutant LCAT allele (n=7, grey 
bars) compared to controls (n=9, white bars). Data are expressed as mean ± SEM.  
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3.7. Baseline mRNA expression of cytokine in monocytes   
 
In addition we measured baseline mRNA expression of cytokines and gene involved in 
cholesterol metabolism. While increased mRNA expression of CD11c was found, other 
gene were expressed similarly between LCAT deficient patients and controls. No 
difference in gene expression was found between carriers and controls, although a trend in 
abca1 and abcg1 was observed, with higher abca1 and abcg1 in genetic LCAT mutations 
(0.72 vs 2.10, P=0.068 and 0.65 vs 2.33, P=0.055 in controls vs LCAT-def) (Figure 34). 
 
 
 
Figure 33. Baseline mRNA expression levels of inflammation genes. Data are expressed 
as mean ± SEM.  
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Figure 34. Baseline mRNA expression levels of gene involved in cholesterol metabolism. 
Data are expressed as mean ± SEM. 
 
3.8. Comparison with other genetic hypoalphalipoproteinemias 
 
To evaluate whether the effect on monocytes was dependent on low HDL-C in LCAT 
deficient subjects, we added to the study a comparison with other genetically determined 
hypoalphalipoproteinemias, as ABCA1 and APOA1 deficiency. Exclusion criteria were the 
previously mentioned. Briefly, absence of cardiovascular or renal disease, diabetes or any 
chronic/acute inflammatory condition. 
In Table 10 are presented the clinical characteristics of the populations and of the control 
group matched by age, gender and BMI. 
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Table 10. Clinical characteristics of carriers of ABCA1 and APOA1 deficiency and control 
subjects 
 ABCA1-def APOA1-def Controls PAnova 
n 10 9 9  
Age (years) 44.7 ± 4.2 45.2 ± 5.2 41.2 ± 4.0 0.801 
Gender (male/female) 3/7 3/6 5/4 0.793 
BMI (kg/m2) 28.4 ± 2.0 27.5 ± 1.9 24.5 ± 1.3 0.165 
Smoking (n,%) 5 (50) 6 (67) 5 (44) 0.615 
TC (mg/dL) 166.2 ± 12.6 125.7 ± 14.1 208.5 ± 9.6 <0.0001 
TG (mg/dL) 155 (81-265) 157 (119-223) 113 (93-128) 0.280 
LDL-C (mg/dL) 109.7 ± 5.5  87.4 ± 15.8 121.5 ± 7.7 0.086 
HDL-C (mg/dL) 31.7 ± 2.7 20.0 ± 1.8 63.4 ± 5.9 <0.0001 
ApoA-I (mg/dL) 76.7 ± 3.4 58.2 ± 5.7 121.1 ± 7.9 <0.0001 
ApoB (mg/dL) 111.2 ± 10.1 84.7 ± 9.0 93.9 ± 2.9 0.077 
Glucose (mg/dL) 90.8 ± 4.2 87.4 ± 6.0 87.1 ± 4.2 0.841 
Statin treatment (n,%) 6 (60) 5 (56) 1 (11) 0.064 
Data are expressed as mean ± SEM for all variables.  
As for LCAT-deficiency, ABCA1 and APOA1 deficiency were not associated with 
increased circulating levels of hsCRP, as well as of other cytokines (Table 11).  
 
 
Table 11. Plasma levels of hsCRP and cytokines in carriers of ABCA1 and APOA1 
deficiency and controls subjects 
 ABCA1-def APOA1-def Controls 
P-
value 
hsCRP (mg/L) 2.2 (0.5-10.3) 1.8 (0.7-7.2) 1.5 (0.8-3.4) 0.485 
MCP-1 (ρg/mL) 42.9 (36.2-59.1) 62.0 (46.6-85.2) 74.4 (32.5-101.5) 0.254 
TNFα (ρg/mL) 2.1 (1.5-2.2) 2.3 (1.7-2.7) 1.8 (1.5-2.3) 0.446 
IL-6 (ρg/mL) 1.0 (0.6-2.2) 1.4 (1.0-3.3) 1.2 (0.8-1.6) 0.346 
Data are expressed as median and interquartile range for all variables. 
 
Notably, hsCRP inversely correlates with the plasmatic concentration of apoA-I in APOA1-
def carriers (Figure 35), but not in ABCA1-def or in the total study populations. 
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Figure 35. Correlations between plasma hsCRP and apoA-I in carriers of APOA1 mutation 
 
Monocyte subsets distribution were comparable in all genotypes, as shown in Figure 36. 
Expression of chemokine, adhesion, transmigration and cholesterol uptake markers on 
blood monocytes (and in all monocyte subsets) was not different between mutations 
carriers and controls, including CD11c expression (Figure 37-Figure 39).  
Interestingly, when activation markers expression on monocytes was assessed with flow 
cytometry, TLR2 expression was higher in APOA1 mutation carriers compared to ABCA1 
and controls, although it was statistically significant only when intermediate and non-
classical monocytes were considered (Figure 40). In a post-hoc analysis, TLR2 expression 
in APOA1-def was higher compared to ABCA1-def (P=0.028 and P=0.034 for intermediate 
and non-classical subset respectively after Bonferroni’s multiple comparisons), while was 
similar compared to controls (Figure 40).  
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Figure 36. Percentage of monocyte subsets (classical (CD14++/CD16-), intermediate 
(CD14+/CD16+), or non-classical (CD14+/CD16++) in carriers of ABCA1 deficiency (n = 10, 
black open circles), APOA1 deficiency (n=9, filled squares) vs. controls (n = 9, grey open 
circles).  
 
 
 
Figure 37. Chemokine, adhesion and transmigration markers on total monocytes as 
assessed with flow cytometry in carriers of ABCA1 (n=10, grey bars) e APOA1 (n=9, black 
bars) deficiency compared to controls (n=9, white bars). Bar graphs display the expression 
(quantified as delta MFI). Data are expressed as media ± SEM. * P < 0.05.  
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Figure 38. Scavenger receptor expression on total monocytes as assessed with flow 
cytometry in carriers of ABCA1 (n=10, grey bars) and APOA1 (n=9, black bars) mutations 
compared to controls (n=9, white bars). Bar graphs display the expression (quantified as 
delta MFI). Data are expressed as media ± SEM. 
 
Figure 39. Activation markers expression on total monocytes as assessed with flow 
cytometry in carriers of ABCA1 (n=10) and APOA1 (n=9) mutations compared to controls 
(n=9). Bar graphs display the expression (quantified as delta MFI). Data are expressed as 
media ± SEM  
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Figure 40. TLR2 expression in different monocyte subset as assessed by flow-cytometry 
in carriers of ABCA1 (n=10, white bars), APOA1 (n=9, grey bars) mutations and controls 
(n=9, black bars). Bar graphs display the expression (quantified as delta MFI). Data are 
expressed as media ± SEM. * P=0.028 and **P=0.034 after Bonferroni’s multiple 
comparisons. 
 
TEM was measured in HAEC on isolated monocytes in carriers of ABCA1 and APOA1 
mutations. As expected we found no difference between groups as depicted in Figure 41.  
Ex vivo stimulation of monocytes isolated from carriers and controls with LPS and 
Pam3Cys did not show any difference in the cytokine production, neither pro-inflammatory 
(Figure 42, Figure 44), nor anti-inflammatory (Figure 43, Figure 45).  
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Figure 41. Transendothelial migratory capacity of monocytes isolated from carriers of 
ABCA1 (n=9, black circles) and APOA1 mutations (n=8, black squares) and controls (n=9, 
grey circles). Data are presented as percentage of transmigrated cells/total monocytes per 
field of view. 
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Figure 42. Pro-inflammatory cytokine production in response to a 24-hour challenge with 
LPS (10 μg/mL) in monocytes isolated from ABCA1 (n=9, grey bars) and APOA1 (n=9, 
black bars) deficient subjects compared to controls (n=7, white bars). 
 
Figure 43. Anti-inflammatory cytokine production in response to a 24-hour challenge with 
LPS (10 μg/mL) in monocytes isolated from ABCA1 (n=9, grey bars) and APOA1 (n=9, 
black bars) deficient subjects compared to controls (n=7, white bars). 
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Figure 44. Pro-inflammatory cytokine production in response to a 24-hour challenge with 
Pam3Cys (10 μg/mL) in monocytes isolated from ABCA1 (n=9, grey bars) and APOA1 
(n=9, black bars) deficient subjects compared to controls (n=7, white bars). 
 
Figure 45. Anti-inflammatory cytokine production in response to a 24-hour challenge with 
LPS (10 μg/mL) in monocytes isolated from ABCA1 (n=9, grey bars) and APOA1 (n=9, 
black bars) deficient subjects compared to controls (n=7, white bars). 
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Figure 46. Baseline mRNA expression levels of inflammation genes. Data are expressed 
as mean ± SEM.  
 
 
 
Baseline expression of genes involved in inflammation (Figure 46) and cholesterol 
metabolism were also measured and no difference was found between carriers and 
controls. Conversely, mRNA of hmgcoar was significantly higher in ABCA1-def and 
APOA1-def compared to controls (P=0.016). The significance was maintained also after 
correction for statin treatment (P=0.034) (Figure 47) 
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Figure 47. Baseline mRNA expression levels of gene involved in cholesterol metabolism. 
Data are expressed as mean ± SEM. *P=0.034 after correction for statin treatment. 
 
3.9. Correlations between mRNA expression of inflammatory markers, 
HDL-C and apoA-I 
Although the number of subjects were too small, we ran some correlations to assess 
whether HDL-C or apoA-I concentrations are associated with mRNA expression of 
inflammatory markers in our study populations.   
Table 12. Correlations between inflammation parameters and HDL-C 
 Total ABCA1 APOA1 LCAT CONTROLS 
Parameter r P r P r P r P r P 
il1β -0.412 0.009 -0.674 0.023 -0.008 0.983 -0.364 0.272 0.643 0.086 
il18 -0.335 0.037 -0.456 0.159 0.234 0.544 -0.236 0.484 0.095 0.823 
~ 89 ~ 
 
 
Table 13. Correlations between inflammation parameters and apoA-I 
 Total ABCA1 APOA1 LCAT CONTROLS 
Parameter r P r P r P r P r P 
il1β -0.325 0.047 -0.354 0.316 -0.301 0.431 -0.191 0.574 0.786 0.021 
il18 -0.323 0.048 -0.305 0.392 0.109 0.781 -0.227 0.502 -0.095 0.823 
 
mRNA expression of IL-1β and IL-18 inversely correlated with plasma HDL-C (r=-0.412, 
P=0.009 and r=-0.335, P=0.037 respectively) as well as with apoA-I (r=-0.325, P=0.047 
and r=-0.323, P=0.048). In addition HMGCoAR expression negatively correlates with HDL-
C (r=-0.391, P=0.014) and apoA-I (r=-0.416, P=0.009). Correlation significance was lost 
when stratified for different genotype.  
 
4. VASCULAR STRUCTURE AND FUNCTION IN CARRIERS OF 
LCAT DEFICIENCY  
 
4.1. Carotid intima media thickness 
 
Figure 48. Carotid intima media thickness measurement in LCAT deficient and control 
subjects. Data are expressed as mean ± SEM; two mutant LCAT allele carriers (n=11, 
black bars), one mutant LCAT allele carriers (n=36, grey bars) compared to controls 
(n=21, white bars); PAnova adjusted for age, gender and family. 
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To evaluate whether a defect in LCAT gene, leading to low HDL-C concentration, is 
associated to cardiovascular disease, carotid intima-media thickness (IMT), as an index of 
subclinical atherosclerosis, was measured on a representative subgroup of subjects,. 
Despite the atherogenic lipid profile, carrying LCAT mutation is not associated with an 
increased atherosclerosis degree. Indeed, maximum carotid IMT was even decreased in 
carriers of two mutant LCAT alleles, compared to controls (0.943 ± 0.224 vs 1.252 ± 
0.159), while carriers of one mutant allele displayed a comparable degree of 
atherosclerosis (1.222 ± 0.105). Moreover, presence of LCAT mutation in our population is 
not associated with differences in mean carotid IMT (Figure 48).  
 
4.2. Flow-mediated vasodilation 
As an in vivo indicator of nitric oxide production and endothelial functionality (195), flow-
mediated vasodilation (FMD) was measured in a small subgroup of patients with LCAT 
deficiency. Heterozygous (n=10) and homozygous (n=5) carriers were pooled together for 
statistical analysis requirement. Characteristics of the included subjects are listed in Table 
14. In accordance with the in vitro findings, despite low HDL-C, carriers of dysfunctional 
LCAT did not show impaired FMD (Figure 49). 
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Table 14. Clinical and biochemical characteristics of carriers of LCAT gene mutations 
included in the FMD assessment 
Data are presented as mean ± SEM.   
 
 
 
Figure 49. Flow-mediated vasodilation in LCAT deficient and control subjects. Data are 
expressed as mean ± SEM; n=35 controls, n=21 carriers (n=10 heterozygotes and n=5 
homozygotes); PAnova=0.18; PAnova=0.22 after adjustment for HDL-C.  
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 Carriers Controls P 
n 15 35  
Age (years) 43.9 ± 3.0 44.1 ± 1.9 0.97 
Gender (male/female) 8/7 19/16 0.95 
BMI (kg/m2) 23.4 ± 0.8 23.7 ± 0.5 0.75 
TC (mg/dL) 160.8 ± 12.0 199.1 ± 6.8 0.005 
LDL-C (mg/dL) 105.2 ± 9.8 124.0 ± 5.3 0.07 
HDL-C (mg/dL) 32.9 ± 5.4 56.1 ± 2.2 <0.0001 
Triglycerides (mg/dL) 113.1 ± 12.4 95.1 ± 9.2 0.27 
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DISCUSSION 
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Endothelial dysfunction is a peculiar aspect of atherosclerosis and is characterized by 
disruption of the vascular homeostasis, mediated by altered balance of substances that 
modulate vascular tone, inflammation and hemostasis. A peculiar switch of endothelial 
surface from non-adhesive to pro-adhesive is also seen (51). A number of studies have 
shown a direct protective effect of HDL on endothelial cells, by promoting the production of 
NO, the most important regulator of vascular tone, and by downregulating CAM expression 
(51, 196). HDL subpopulations have demonstrated different efficiency in maintaining 
endothelial cells homeostasis (197) and in some conditions can lose their positive 
properties (198). Although genetic LCAT deficiency is characterized by extremely low 
HDL-C, there is no clear evidence of increased atherosclerosis associated with the 
disease and some studies have even shown a protective effect of the lack of LCAT (199). 
Thus we hypothesized that this increased protection was dependent on an enhanced 
functionality of HDL in protecting against endothelial dysfunction.  
The project was split in two parts: (i) studies on endothelial cells and (ii) studies on 
monocytes.  
(i) Studies on endothelial cells 
HDL particles distribution is altered in carriers of LCAT mutations, that have a reduced 
content of large HDL2 and accumulate small HDL3 particles, mainly immature preβ-HDL 
(18, 99). Selective depletion in HDL containing apoA-II can be also appreciated (200). It 
has already been demonstrated that HDL in LCAT deficiency are more capable in 
promoting ABCA1 efflux from peripheral cells, since preβ-HDL content is more prominent 
in the serum of patients (59), but not data were available so far on the ability of HDL in 
LCAT to promote NO production. NO plays a central role in maintaining vascular tone and 
HDL can stimulate eNOS expression and activation in endothelial cells (201-203). This 
process involves the binding of apoA-I to SR-BI (78) and thus the activation of the 
PI3K/Akt signalling pathway, with the subsequent phosphorylation of eNOS (78, 204). HDL 
isolated from carriers showed an increased ability in eNOS activation, resulting in an 
increased NO production. Interestingly the effect was gene-dose dependent. The selective 
(and gene-dose dependent) depletion of LpA-I:LpA-II particles compared to LpA-I could 
account for this increased capacity. Indeed, while the role of apoA-I is crucial for eNOS 
activation, as demonstrated by the suppression of NO production in endothelial cells with 
anti-apoA-I antibody (78), apoA-II presence is detrimental, since anti-apoA-II antibody 
further enhance eNOS stimulation (78). Accordingly, HDL in CETP deficiency are enriched 
in LpA-I:A-II and showed reduced ability in stimulating NO production (87). We have 
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shown that synthetic HDL containing only apoA-I are more efficient in promoting 
endothelial NO production, likely due to the change in conformation of apoA-I induced by 
apoA-II (205).  
In addition to the presence of apoA-II itself, other protein transported by HDL could 
account for the enhance efficacy of HDL in LCAT deficiency. 
Among other, PON1 has been suggested to have a major impact on endothelial function 
and PON1 inactivation results in decreased eNOS phosphorylation (193) confirmed in 
animal studies where PON1-deficient mice fail to stimulate NO production that was 
restored after PON1 supplementation (193). PON1 is preferentially found in LpA-I particles 
and apoA-I seems to contribute to PON1 stability (206) while apoA-II can displace this 
enzyme. Carriers of LCAT deficiency have normal PON1 activity despite the low HDL-C 
levels (207).  
It must be underlined that the large part of patients included in this study had FLD, thus the 
result of this study may not apply to FED. Indeed in other study, where mainly FED were 
included, an increased arterial stiffness was measured (161), supporting the clinical 
distinction between FLD and FED (183). 
 
(ii) Studies on monocytes 
In the second part of the project, to complete the assessment on endothelial functionality, 
the effect of genetic LCAT deficiency on monocytes phenotype and functionality was 
evaluated for the first time. Endothelial cells activation leads to monocyte recruitment from 
the blood stream, that represents the initial stage in the atherosclerotic plaque formation 
and it is mediated by chemoattractants, cell adhesion molecules and their receptors (208). 
Many studies suggested that the proportion of intermediate monocytes is increased in 
CVD patients (209), inversely associated with apoA-I and HDL-C levels (210, 211), and 
independent predictors of major clinical event (209). More recently researchers suggested 
a role in endothelial dysfunction of non-classical CD14+/CD16++ monocytes (212). 
Hypoalphalipoproteinemia was previously associated with a different prevalence of 
classical CD14++/CD16- but not of intermediate CD14++/CD16+ monocytes (213). Despite 
low HDL-C, we found no difference in circulating monocyte subset distribution in carriers of 
LCAT deficiency, which supports absence of increased atherosclerosis in LCAT mutation 
carriers. 
Murphy and colleagues have shown that in vitro incubation of monocytes with HDL 
reduces both CD11b expression and monocyte adhesion to endothelial cells, similarly to 
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lipid-free apoA-I (214) supporting the role of HDL in preventing monocyte recruitment. 
Opposite observation came from our study, where monocyte of LCAT deficient patients 
showed a comparable expression of CD11b, but a reduced expression of the similar 
integrine, CD11c. The reduction was recapitulated throughout all monocyte subset and 
was gene dose dependent, supporting a discriminatory role of the presence/absence of 
LCAT on monocyte immunophenotype. CD11c is a β2 integrin that promotes the firm arrest 
of monocytes on endothelial cells, through the interaction with vascular cell adhesion 
molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1). Deficiency of 
CD11c has been shown to decrease monocytes adhesion in mouse, reducing 
monocyte/macrophage accumulation in atherosclerotic lesion and decreasing 
atherosclerosis development in apoE-/- mice on high fat diet (215). Moreover, CD11c 
expression is increased in inflammatory condition, e.g. during hypertriglyceridemia  (216). 
Interestingly, the decrease in CD11c expression seen in our study was accompanied by a 
reduced migratory capacity of isolated monocytes in HAEC pre-stimulated with TNF-α, to 
mimic endothelial dysfunction, supporting once again the less inflammatory phenotype of 
monocyte in genetic LCAT deficiency.  
In this study we provided additional characterization of monocyte by challenging them with 
TLR2 and TRL4 ligands (LPS and Pam3Cys) and measuring cytokine production. It has 
been previously shown that HDL are able to inhibit TLR-induced production of 
proinflammatory cytokines from macrophages, acting at transcriptional levels. Activating 
transcription factor (ATF3) was identified as an HDL-inducible negative regulator of 
macrophage activation (217). Once again, despite the severe HDL deficiency, monocytes 
from carriers stimulated with TLR-ligands did not show increased production of TNF-α and 
IL-6, while IL-8 production was even reduced. Notably unstimulated monocytes displayed 
a significantly reduced MCP-1 production compared to controls, although comparable 
circulating levels of MCP-1. Very few reports are present so far about monocyte in LCAT 
deficiency. The studies are limited to murine model that are not fully translatable to human. 
Petropoulou and colleagues showed that mice lacking LCAT had on one hand increased 
systemic responsiveness to LPS, likely due to a decrease LPS-neutralizing ability of 
immature HDL, but on the other hand an increased number of circulating monocytes 
associated with a reduced pro-inflammatory phenotype (218). The mechanism by which 
HDL and apoA-I inhibit monocyte activation was demonstrated to be independent from 
HDL-stimulating NO production (219-221) and dependent on cholesterol efflux capacity, 
since the non-specifically cholesterol removal exerts similar anti-inflammatory effect (214). 
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Accordingly, the ability of subject’s HDL to inhibit monocyte chemotaxis was highly 
correlated with its capacity to promote cholesterol efflux (222).  
Thus we speculated that the decreased inflammatory activation of LCAT deficiency 
monocyte can be possibly explained by the increased cholesterol efflux capacity of the 
HDL in this genetic disorders. The higher concentration of immature preβ-HDL can 
enhance the ABCA1 cholesterol efflux from cells (59) and the consequent cholesterol 
depletion from monocytes can disrupt the intracellular signalling in specific membrane 
microdomains enriched in cholesterol and sphingolipids, called lipid rafts (214, 223). In 
support to this hypothesis Thacker et al. demonstrated that HDL reduces inflammation in 
response to cholesterol crystals in THP-1 cells and in human-monocyte-derived 
macrophages, but the reduction with rHDL (phospholipid and apoA-I only) was greater 
(224), suggesting also in this case a possible importance for the conformation of apoA-I in 
mediating the anti-inflammatory effects. 
Since LCAT is not expressed in monocytes, but monocyte isolated from LCAT deficient 
patients have been in a LCAT-poor milieu, characterized by a peculiar lipoprotein profile, it 
might be possible that these cells could have been “primed”. Epigenetics modification 
could have occurred, as has been already observed for other  lipid disorders (225), but the 
exact mechanisms by which LCAT deficiency supports an “anti-inflammatory phenotype” 
still have to be unravelled. 
Finally, we compared findings about monocytes in LCAT deficiency with other genetic HDL 
deficiency as ABCA1 and apoA-I deficiency. As mentioned before, cholesterol efflux 
seems to largely account for the reduction in anti-inflammatory potential exerted by HDL, 
since modification in cholesterol trafficking in rafts disrupt the inflammatory signalling in 
cells. Macrophages lacking ABCA1 exhibit enlarged cholesterol-rich lipid rafts, with higher 
content of TLR4 and increased responsiveness to TLR2 and TLR4 stimulation (226, 227). 
ApoA-I, by promoting cholesterol efflux through ABCA1 may contribute to the modulation 
of inflammatory response (214). In fact, apoA-I reduces the migration of TLR4 into lipid 
rafts, thus preventing TLR4-mediated NF-kB activation in endothelial cells (227). 
In the recent work by Westerterp and collegues it was reported that ABCA1/ABCG1 
deficiency, leading to intracellular cholesterol accumulation, activates the NLRP3 
inflammasome promoting neutrophil infiltration in LDLR -/- mice (228). In addition patients 
with Tangier, carrying a completely dysfunctional ABCA1 are unable to support cholesterol 
efflux to apoA-I (214) and display elevated plasma levels of inflammatory cytokine (228). 
Surprisingly, taking into account what was known so far about HDL and monocytes, we 
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didn’t find any striking difference in monocyte phenotype and functionality in this HDL-
related disorders. Total monocytes TLR2 expression was comparable between ABCA1, 
APOA1 mutation carriers and controls, but was significantly increased in APOA1-def when 
monocyte subset expression was considered. Probably this inconsistence was dependent 
on patient selection that represents one of the major limitations of the study. All patients of 
ABCA1 and APOA1 mutations were carriers of only one mutant allele, that imply a residual 
number of effective HDL particles that might be sufficient to maintain an healthy 
immunophenotype or other pathway might be involved (214). This finding was however in 
line with genetic studies, where lower plasma levels of HDL-C due to heterozygosity for 
loss-of-function mutations in ABCA1 were not associated with an increased risk of 
ischemic heart disease (229).  
To summarized, in the present work we showed that (i) HDLs in LCAT deficiency have an 
increased capacity in protecting against endothelial dysfunction (ii) the enhance ability to 
promote NO production was dependent on the selective depletion in LpA-I:A-II particles 
(iii) monocytes from patients with LCAT deficiency do not display pro-inflammatory 
immunophenotype and migratory changes.  
Together, these findings contribute to explain the lack of association of genetic LCAT 
deficiency with cardiovascular disease and indeed, confirmatory findings are shown in 
vivo, where carotid IMT, as an index of atherosclerosis, is not increased in carriers 
compared to controls despite the reduced HDL-C levels. Actually, maximum IMT was 
lower in two mutant LCAT carriers compared to non carriers, while one mutant LCAT 
carriers display comparable thickness. In addition FMD, a marker of endothelial 
dysfunction is comparable in carriers and controls. Thus suggesting that the increased 
functionality of HDL might overcome their reduced concentration. However, how it can be 
translatable to the general populations is still matter of debate. The EPIC-Norfolk 
prospective study found no association between LCAT concentrations and CV risk (171), 
while others associated increased LCAT levels with preclinical atherosclerosis in female 
(173). LCAT activity is increased in disease associated with high CV risk, e.g. metabolic 
syndrome (174, 177, 230), but others report showed the opposite (181) (231).  
Limitations: 
The results should be interpreted with caution. A possible limitation of our approach is that 
our conclusions are based on data obtained from ex vivo experiments from a small 
number of low HDL-C subjects. Selection bias have to be taken into account, particularly 
for the monocyte study, since, due to the rareness of the disease, we included mainly 
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patient with only one mutant allele. For the monocyte study we have selected patients free 
of CVD, diabetes, renal disease or other inflammatory condition, hence our considerations 
could not be applicable to advance status of the disease.  
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